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Chapter 1
Introduction
Vaults: Ribonucleoprotein particles involved in drug
resistance?
Marieke H. Mossink, Arend van Zon, Rik J. Scheper, Pieter Sonneveld
and Erik A. C. Wiemer.
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The Discovery of Vaults
In 1986 a novel, large-sized ribonucleoprotein complex was first described (1). The
barrel-shaped structures were initially detected in preparations of clathrin-coated
vesicles from rat liver and because they showed a morphology that resembled the
vaulted ceilings in cathedrals, the structures were named vaults. It is now known that
structures of similar dimension, morphology and composition are present in cells of
diverse organisms like protozoa, molluscs, the slime mold Dictyostelium
discoideum, echinoderms, fish, amphibians, avians, and mammals (2, 3). The high
degree of conservation of this large complex points to an important cellular function.
Vaults could not be detected in Saccharomyces cerevisiae (4) and are probably not
present in Caenorhabitis elegans, Drosophila melanogaster and the plant
Arabidopsis spec., i.e., no clear vault protein orthologs could be detected in the
genomes of these organisms.
The Structure of the Vault Complex
The vault complex is 35 x 65 nm in size and has an estimated molecular mass of 13
MDa (5), making it the largest ribonucleoprotein complex known, in fact three times
the size of a ribosome.
Initial electron-microscopical micrographs showed that vaults have two centers of
mass, suggesting the vault complex has two symmetrical halves. Indeed, it was
shown that the complex can fall apart in two halves which can unfold into flower-
like structures (5). Each flower consists of 8 distinct petals that are joined to a
central ring.
Recently cryo-electron microscopy combined with three dimensional image
reconstruction techniques revealed the vault structure at a 22 Å resolution (6, 7).
Vaults appear to be typical hollow barrel-like structures with an 8-2-2 symmetry.
Each vault particle has an invaginated waist and two protruding caps (Figure 1).
The Components of the Vault Complex
The vault complex consists of three different proteins of 100, 193 and 240 kDa. The
100 kDa subunit is dominantly present, and hence called Major Vault Protein
(MVP). This protein makes up over 70% of the total mass of the complex and is the
main structural component. A coiled coil domain at the C-terminal end of the MVP
molecule is responsible for the interaction between two MVP molecules, and thereby
crucial for the assembly of vault particles (8). Furthermore, two and possibly three
calcium binding EF-hands have been identified in a repeat structure near the N-
terminus (8). Calcium binding by MVP, which was shown in vitro assays, could play
a role in the proper folding of the MVP molecules into the vault particle.
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Emphasizing the importance of MVP for the structure of vaults is a report by
Stephen et al., indicating that the expression of MVP in insect cells which are
lacking vaults, is sufficient for the assembly of particles highly similar to intact vault
particles (9).
Figure 1. Reconstruction of the vault complex at a 22 Å resolution. Using single-particle
reconstruction techniques, approximately 3500 particle images obtained by cryo-electron
microscopy were combined to generate the three dimensional image of the vault complex
(A), including two cropped views (B). Clearly visible are the symmetrical hollow barrel-
shaped structure and two protruding caps. Note that the vault complexes used were RNase
treated, resulting in a slightly reduced density at the end of the caps. The scale bar
corresponds to 250 Å. Figure reproduced from Kong et al. (7) with permission from the
Cambridge University Press.
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The two other vault proteins of 193 and 240 kDa are designated minor vault proteins
(MiVP). The minor vault proteins are thought to be localized in the protruding caps
of the vault complex. In these caps, also multiple copies of the vault RNA (vRNA),
small untranslated RNA molecules of 88-141 nucleotides are present. A model has
been proposed in which vaults contain 96 copies of MVP, and in each of the caps
one molecule of TEP1, four molecules of VPARP and three or more copies of
vRNA (7). The vault RNA constitutes less then 5% of the mass of the complex and
was found not to be a structural compound of the vaults complex, since degradation
of RNA did not alter the complex structure (1, 7, 10). Interestingly, in human cells
three related vault RNAs are expressed, called hvg1, 2 and 3, of 98, 88 and 88 bases
in size, respectively. Other species like rat and mice only express one vRNA, of 141
bases, and two vRNAs of 89 and 94 bases are found in bullfrog (11-13). The reason
for the existence of multiple vRNAs in some species is unknown. It has been shown
however, that all three human vRNAs are bound to the vault complex, although not
in equimolar amounts. Furthermore, a pool of unbound vRNA must exist in the cell,
as only around 20% of the expressed vRNA was found to be associated with the
vault complex in human cancer cells (11, 12).
In 1999, Kickhoefer et al. reported the cloning of both minor vault protein cDNAs.
The 240 kDa protein was identified as TEP1, a protein also associated with the
telomerase complex (14). Within the telomerase complex, the function of TEP1 is
still unknown. It was shown to specifically interact with the telomerase RNA (15)
and also with the vault RNAs (14). Since only two components of the telomerase
complex seem essential for its function in vitro, namely TERT and the telomerase
small RNA (hTR), TEP1 was thought to be a structural component (16, 17). Indeed
as was shown recently in a TEP1 deficient mouse model, this protein is not essential
for telomerase activity. Moreover, telomere length was also unaffected after
disruption of TEP1 (10). The consequences of TEP1 disruption for the vault
complex were investigated by Kickhoefer et al. (18). Vault particles seemed
unaltered at first, but closer investigation revealed a decreased electron density at the
extreme ends of the caps of the vault structures. Whereas absence of TEP1 did not
influence the levels of telomerase RNA associated with the telomerase complex, the
association of vRNA with the vault complex was completely disrupted. In addition,
the level of vRNA and its stability were found to be markedly decreased in tissues of
the TEP1 knockout mice. The biological significance of the shared subunit for both
the telomerase complex and vault complex has not been demonstrated yet. Should
TEP1 be interpreted as a link between the two ribonucleoprotein complexes, or do
both complexes simply use the features of the TEP1 protein in their own way for
their own functioning? Information of the function of TEP1 in one complex might
give clues for its function in the other.
The 193 kDa subunit is called VPARP, since it contains a functional poly(ADP-
ribose) polymerase (PARP) domain (19). This PARP domain can catalyze the
covalent addition of ADP-ribose units to acceptor proteins. The first protein reported
to have PARP activity (PARP-1) is a nuclear enzyme that was shown to bind tightly
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to nicked DNA and that is involved in the base excision repair pathway (for a review
see Ref. 20). Next to VPARP and PARP-1, five other proteins with a PARP domain
have been described so far. PARP-2, showing the highest homology to PARP-1, is
also involved in base excision repair and can heterodimerize with PARP-1 (21). The
PARP domain containing proteins tankyrase-1 and tankyrase-2 are associated with
telomeres and might act as telomere-length regulators. Both proteins bind to the
telomeric protein TRF1 and the ADP-ribosylation of TRF1 reduces its ability to bind
telomeric DNA (22, 23). Two other PARP family members have been identified,
PARP-3 and TiPARP, but have not been well characterized yet (24, 25). Although
having a similarity of 29-60% between their PARP domains, the PARP proteins
show no homology other outside this domain (26). The unique features of each of
these proteins might thus point to different functions in the cell. VPARP was shown
to be capable to ADP-ribosylate itself as well as the major vault protein, but this
activity was not yet shown to be of functional importance within the vault complex.
Besides being an integral part of the vault particle, VPARP is also located in the
nucleus, where it is not associated with other vault components (19). In this respect
it is interesting to note that VPARP contains a BCRT domain, a widespread motif in
proteins involved in DNA damage repair, which is also used by PARP-1 for its
interaction with the base excision repair complex protein XRCC1 (27). These
findings might imply a role for VPARP in DNA damage repair, similar to PARP-1
and PARP-2.
The Intracellular Localization of Vaults
The number of vaults per cell has been estimated from as many as 10.000 to 100.000
copies (12). The majority of these reside in the cytoplasm where they may interact
with cytoskeletal elements like the ends of actin stress fibres in rat fibroblasts (28)
and in the tips of differentiated PC12 cells (29) or microtubules (30). Several groups
reported the association of vaults with the nucleus, in particular the nucleoli, the
nuclear membrane and/or the nuclear pore complex (30-32). In general, in
mammalian cells approximately 5% of the total vault fraction is found associated
with the nucleus.
The Function of Vaults
Despite the increasing interest in the vault complex over the past years, its function
has still not been elucidated. However, several functions have been proposed in the
literature. For instance, a role in intracellular transport, in particular nucleo-
cytoplasmic transport, has been suggested. This idea is based on the subcellular
localization and distinct morphology of the complex. The partial co-localization of
vaults with cytoskeletal elements (3, 29, 30) and the location of vaults near secretory
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organelles in nerve growth factor treated PC12 neuron-like cells (29) has led to the
suggestion that vaults are transported along the cytoskeletal elements, in particular
microtubuli. Evidence supporting this comes from Li et al., who showed that vaults
are actively transported within axons between the soma and the nerve terminal (33).
Chugani et al. proposed that vaults are acting as shuttles between nucleus and
cytoplasm (31). A possible cargo for the vault-mediated transport was reported in
studies in developing sea urchin embryo’s where MVP was co-purified with
ribosomes, leading to the suggestion that vaults are involved in the transport of
ribosomes (30). Another possible cargo of the vault complex was postulated by
Abbondanza et al., who found an association of MVP with the estrogen receptor and
other steroid hormone receptors (32) and suggested a role for vaults in the nuclear
targeting of these receptors and hence in the signal transduction of steroid hormones.
The hollow structure of the complex fits well with the idea of vaults being involved
in cellular transport (6). The internal cavity is about 5 x 107 Å3 in size, making it
large enough to contain particles such as ribosomes. Indeed, cryo-electron
microscopy images show electron dense material within the isolated vault particles
(6). The nature of this cargo, however, is still unknown. The identification of the
vault’s cargo might shed a light on the function of the vault complex.
Unlike in other organisms, three different MVP genes, that code for MvpA, MvpB
and MvpC of 94, 92 and 92 kDa respectively, are present in Dictyostelium (34, 35).
Disruption of two of the three MVP genes led to a growth defective phenotype under
nutritional stress, suggesting a role in fundamental processes such as proliferation
and cell survival. A recent report suggests that vaults are upregulated during the
differentiation and maturation of dendritic cells, and are possibly involved in the
antigen presenting function of dendritic cells (36).
In general, MVP and vaults are believed to play a role in multidrug resistance. In
1993 a 100 kDa protein was found to be overexpressed in non-small cell lung cancer
cells that were selected for doxorubicin resistance (37). This protein was initially
named lung resistance-related protein, LRP. Since the identification of LRP as the
human MVP (38), the involvement of vaults in drug resistance has become a subject
of study.
If vaults play a role in cellular protection against toxic compounds, the way by
which they contribute to MDR is clearly different from the known mechanisms of
drug resistance, notably the extrusion of drugs by various ABC transporters. Based
on its subcellular localization, structural characteristics and components it was
speculated that vaults act by transporting drugs away from their subcellular targets.
Vaults may be involved in nucleo-cytoplasmatic transport and/or the sequestration of
drugs into intracellular compartments. In addition to the transport of drugs, vaults
may play a role in protecting DNA against drugs or in the maintenance of genome
stability, functions that are implied by the characteristics and localization of the two
minor vault proteins, TEP1 and VPARP (see Figure 2).
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Figure 2. Schematic view of the hypothetical role of vaults in nucleo-cytoplasmatic and
vesicular transport of drugs and/or metabolites. Vaults may be involved in the
intracellular compartmentalization and/or transport of biomolecules, particularly as it
concerns nucleo-cytoplasmic transport (1&2). Vaults may mediate multidrug resistance by
transporting drugs away from their intracellular targets e. g. the nucleus (2) or by transporting
them to efflux pumps (3) or exocytotic vesicles (4). Based on the characteristics of the minor
vault proteins, vaults or vault components are possibly involved in the maintenance of
genomic stability, indicated by an asterisk (5). Open arrows represent diffusion and black
arrows represent active directional transport. Black dots indicate drugs and biomolecules.
A very subtle mechanism of the regulation of resistance was proposed recently by
van Zon et al. (11). In human tumor cell lines, all three expressed human vRNAs
(hvgs) were found associated to the vault complex, but the ratio of associated hvgs
differed in the various cell lines examined and it was observed that increasing
amounts of hvg3 were associated with vaults isolated from drug resistant cell lines,
when compared to the drug sensitive parental cells. This finding implies that the
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ratio of associated hvgs might influence the function or activity of vaults in drug
resistance. However, this way of regulation of resistance would be specific for
human cells, as rat and mice only express one vRNA. Differential association of the
two bullfrog vRNAs with vaults has not been investigated yet.
The possible existence of vault-mediated drug resistance and the specific drugs
involved have been investigated by many groups, using cell lines derived from
various human tumors. Furthermore, many clinical studies have investigated the
significance of MVP as a prognostic factor.
Vaults and Multidrug Resistance
MVP is found widely distributed in normal human tissues. However, the expression
levels of MVP, as well as TEP1, have been found to be relatively high in cells and
tissues that are chronically exposed to xenobiotics, such as in lung, epithelial cells in
the digestive tract, macrophages and dendritic cells (3, 36, 39), suggesting a role in
the defense of these organs against toxic compounds. A second indication for a role
of vaults in drug resistance is the overexpression of the vault components MVP and
VPARP mRNA and protein, in multidrug resistant tumor cells. Furthermore,
overexpression of MVP proved to correlate with increasing levels of resistance in
various human cancer cell lines (37, 40).
No specific substrate for vaults has been identified yet and elevated levels of MVP
have been found in cell lines resistant to various cytotoxic agents. These drugs
include doxorubicin, mitoxantrone, methotrexate, etoposide, vincristine, cytarabine
and cisplatinum (37, 41-45). Additionally, correlation of MVP expression with
resistance to various drugs has been reported. Berger et al. all showed that MVP
expression levels, both protein and mRNA, correlated with resistance to cisplatinum
in non-small-cell lung cancer cells. No correlation was observed with resistance to
daunomycin, bleomycin, doxorubicin, etoposide and vinblastine in this study (46). In
contrast, in pharyngeal carcinoma KB-3-1 cells, increased MVP levels were found to
correlate with decreased accumulation of doxorubicin in the nuclei of these cells
(47). Another recent study performed in U-937 leukemia cells reports that cells
selected on doxorubicin upregulated vault levels and acquired resistance against
doxorubicin, etoposide and mitoxantrone. This resistance seemed to be independent
of MDR1, MRP1, MRP2 and BCRP (48). Kitazono et al. claimed direct involvement
of MVP levels in the resistance to doxorubicin, etoposide, vincristine and taxol. In
their studies, the colon cancer cell line SW620 was treated with sodium butyrate
leading to an upregulation of MVP and a multidrug resistant phenotype. When the
MVP mRNA levels were reduced by the expression of MVP specific ribozymes, the
cells were significantly less resistant. Furthermore, isolated nuclei of sodium
butyrate treated SW620 cells incubated with an IgG fraction of polyclonal anti-
(MVP) antiserum accumulated more anthracycline then nuclei of cells in absence of
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these antibodies, suggesting that MVP is important in the extrusion of anthracyclines
from the nucleus (49, 50).
Stable transfection of an ovarian carcinoma cell line which expresses no or very low
levels of vaults, with an MVP expression construct did not confer drug resistance
(38). Initially, this was explained by the fact that MVP only comprises 70% of the
vault particle and additional factors, e.g., the minor vault proteins and/or vRNAs are
essential for proper vault function. Indeed, in resistant tumor cells the upregulated
levels of MVP actually represent an increased number of vault copies (12, 51).
However, recently it was reported that the stable MVP transfectant cell line
mentioned above in fact also contains elevated levels of TEP1 and VPARP and an
increased number of intact vault particles (40). Apparently, vaults may be necessary
but are not sufficient for drug resistance.
Vaults as a Prognostic Marker
The hypothesis that MVP expression is part of a novel pathway of multidrug
resistance has prompted several clinical studies to determine the expression of this
molecule in human tumors. These studies have mainly focused on the question
whether MVP expression levels are predictive of the clinical outcome after
chemotherapy. The majority of the studies have been performed in hematological
malignancies. Various detection techniques of MVP expression have been used,
including immunofluorescence, immunocytochemistry, RNA expression as
determined by RT-PCR and protein blotting. The results obtained with these
detection assays are variable. Ultimately, a functional assay of MVP activity is
needed since earlier studies with P-glycoprotein have demonstrated the superiority
of such an assay for the correlation of in vitro drug resistance with clinical response
and prognosis. Thus far, the evidence that MVP expression correlates with clinical
Reponses is weak, in particular when small numbers of patients were investigated.
Another limitation is that most studies have been founded on univariate analysis,
without evaluating other prognostic parameters. Thus, more compelling evidence
that MVP expression correlates with the clinical response and prognosis is still
lacking and should come from a prospective trial using a functional assay and a
multivariate analysis of risk factors.
Acute Myeloid Leukemia (AML)
MVP is expressed in 5 to 61% of AML patients at diagnosis (52-64). Unlike P-
glycoprotein, the expression at relapse or in refractory disease is not elevated as
compared to the levels at diagnosis. Several investigators have proposed a negative
prognostic significance of MVP expression on the probability to attain a complete
response, progression-free survival (PFS) or relapse-free survival (RFS) and overall
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survival (OS) (53-60). In contrast, other studies did not point towards a prognostic
significance of MVP on either outcome variable (52, 61-64). In only a few studies it
has been attempted to analyze the prognostic significance of MVP in relation to
other drug resistance proteins such as P-glycoprotein (P-gp) or the multidrug
resistance-related protein (MRP1). In studies searching for co-expression of these
proteins, simultaneous positivity was observed in 5-24% of cases. In general, the
worst response and/or survival was observed in patients who co-expressed P-gp and
MVP, while the best prognosis was seen in patients who were negative for both
proteins (53, 54, 56, 57). No correlation between MVP expression and other
prognostic variables such as FAB classification, older age, high white blood cell
count or unfavorable karyotype have been found (63-66). From the currently
available data it can be concluded that MVP expression is observed in a considerable
proportion of the patients, but no conclusive evidence exists regarding its prognostic
significance.
Acute Lymphoblastic Leukemia (ALL)
Relatively few studies have addressed the role of MVP in ALL. In childhood ALL, a
category of ALL with a relatively good prognosis, the proportion of positive patients
ranges from 10% at diagnosis up to 68% at relapse (67-70). In childhood ALL,
reduced intracellular retention of daunorubicin in vitro seems to be associated with
increased MVP expression, rather than with P-gp or MRP. Moreover, this was
associated with a higher level of in vitro drug resistance in general (67, 68). These
data suggest an important role for MVP in the development of resistant disease in
ALL. Another group pointed to the higher incidence of MVP expression at relapse
(68%) as compared to diagnosis (47%), which suggests that MVP expression can
either be induced during chemotherapy or is selected for through prior treatment.
Again, there seems to be no significant correlation with other prognostic parameters
in ALL. MVP expression may be higher in leukemias with a pre-B cell origin as
compared to T cell ALL. None of these studies seriously addressed the prognostic
impact of MVP expression on the outcome of chemotherapy, primarily because of
the small size of the patient groups (69-71). Currently, the role of MVP expression is
prospectively evaluated in several clinical studies.
Multiple Myeloma (MM)
In MM expression of MVP is observed in 47-74% of untreated patients (55, 72-74).
Three studies have addressed the prognostic significance of the protein using
immunocytochemistry. In all studies MVP expression is associated with relative
resistance to standard treatment with Melphalan based regimens. However, this
relationship was found only in patients who were treated with conventional dose
melphalan and not in patients receiving escalating dosages (73). Taken together,
these observations warrant further investigations to the role of MVP in drug
resistance in MM.
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Solid tumors
Relatively few studies have addressed the role of MVP in solid tumors. Two studies
from the same group have dealt with the expression of MVP in ovarian cancer (75,
76). In advanced ovarian cancer (FIGO stage III/IV) 77% of the patients express
MVP at diagnosis. In localized cancer (FIGO stage I/II) a same figure is observed. In
advanced ovarian cancer a correlation was found between MVP expression and lack
of response and/or shorter OS. This was not found in early stage ovarian cancer. In
contrast, in early stage ovarian cancer, MVP expression was associated with
favorable prognostic variables.
Two studies were performed in breast cancer which both used
immunohistochemistry to investigate MVP expression. In one study the expression
ranged from 69 to 75% without significant differences between samples obtained at
diagnosis or at relapse after chemotherapy (77). The second study found 68% of
patients with intermediate or high MVP expression (78). In neither study a clear
correlation with clinical outcome was observed.
Other tissues that express a high level of MVP include bronchial epithelium,
coecum/rectum, colon and other epithelial tissues. In cancers derived from these
tissues a variable expression of MVP is observed. For example, in non-small cell
and small cell lung cancer the expression is different with the highest expression
found in chemo-resistant non-small cell lung cancer (78). As in another study, no
correlation with relevant clinical or clinicopathological parameters was observed
(69, 79).
The strongest expression of MVP is found in colorectal tumors. In this tumor the
expression increases from premalignant lesions such as colonic adenoma to
aggressive colon carcinoma, which indicates that MVP may be associated with more
aggressive disease (39, 80). Other tumors in which expression of MVP has been
reported include melanoma, osteosarcoma and neuroblastoma. In melanoma a high
expression is observed, which seems to correlate with aggressive behaviour of the
tumor, such as in primary choroidal melanoma (81, 82). Since this tumor type rarely
responds to chemotherapy, the relevance for drug resistance remains unclear. In
osteosarcoma, MVP expression was reported to correlate with failure to
chemotherapy and poor survival (83).
Aims and outline of the thesis
Although MVP is often found to be highly expressed in tumor cells and is
sometimes clearly upregulated as a consequence of drug treatment, results on
correlation of expression levels with resistance to various drugs are contradictory.
True evidence for a role of vaults in drug resistance is lacking.
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The aim of this study was to determine whether vaults play a role in drug resistance
and to reveal other possible physiological functions of vaults. Since MVP is the
major component of the vault complex, we focussed on this particular component.
Assuming that disruption of MVP would also lead to disrupted vault particles, we
choose to generate a MVP knockout mouse model. Chapter 2 describes the cloning
and characterization of the murine MVP cDNA and gene, including its promoter.
Chapter 3 deals with the preparation of the target construct, used to knockout MVP
in embryonic stem cells, and the subsequent generation of the MVP deficient mice.
Furthermore, this chapter shows an extensive investigation of the sensitivity of these
mice (and cells derived from these mice) to various cytostatic drugs. The
biochemical effects of absence of MVP on the vault complex are reported in Chapter
4.
Besides a possible role in drug resistance, some other possible vault-functions have
been suggested in literature, such as an involvement in the development of dendritic
cells and in DNA repair mechanisms. The MVP knockout mouse model provided a
useful tool to investigate these hypotheses. In Chapter 5, the development of
dendritic cells from MVP deficient bone marrow cells and the immune response of
MVP deficient mice were examined. In Chapter 6, an involvement of VPARP and/or
vaults in DNA damage repair mechanisms is studied.
Finally, Chapter 7 gives a general discussion of the work presented in this thesis.
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Abstract
Vaults are ribonucleoproteins of unknown function, consisting of three different
proteins and multiple copies of small untranslated RNA molecules. One of the
protein subunits has been identified as TEP1, a protein that is also associated with
the telomerase complex. Another protein appears to contain a functional PARP
domain and is hence called VPARP. The third protein, major vault protein (MVP) is
believed to make up 70% of the total mass of the vault complex and to be
responsible for the typical-barrel shaped structure of vaults. We have isolated the
murine MVP cDNA and compared the amino acid sequence with MVP from other
species. Over 90% of sequence identity was found between mouse, human and rat,
and a considerable degree of identity between mouse and MVPs from lower
eukaryotes. We also found that the genomic structure of the murine MVP gene
closely resembles the organization of the human MVP gene, both consisting of 15
exons of which most have exactly the same size. Finally we have isolated a genomic
region upstream (and partially overlapping) the first untranslated exon, that
displayed promoter activity in a luciferase reporter assay. Furthermore we showed
that the sequences from the first exon together with the 5’ end of the first intron
enhance the promoter activity, implying the presence of essential promoter elements
in this region. Alignment of the murine promoter region with the homologous
sequences of the human gene revealed an identity of 58%. The apparent presence of
conserved promoter elements suggests a similar regulation of human and murine
MVP expression.
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Introduction
The mammalian vault complex is a ribonucleoprotein particle that consists of three
different proteins, a 100 kDa major vault protein (MVP), two minor vault proteins
(MiVP) of 193 and 240 kDa, and multiple copies of untranslated RNA molecules of
around 100 bases. (For a review see Ref. 1). The major vault protein constitutes over
70% of the mass of the total complex (2). The molecular mass of MVP from various
species differs slightly, from 96 kDa in mouse to 99 kDa in humans and rat. The
overall amino acid identity is approximately 90% between mammalian MVPs (see
this manuscript). In Dictyostelium discoideum two, and possibly three MVP genes
have been found (3). In all other organisms examined, only one MVP  gene is
present. A recent paper describes the assembly of vault-like particles in insect cells
only expressing MVP (4). These data support the idea that MVP is the most
important structural element of the vault particle.
The cDNAs encoding the human minor vault proteins were cloned and characterized
by Kickhoefer et al. (5, 6). They showed that the 240-kDa subunit is identical to
TEP1, a protein associated with the telomerase complex. Except for the association
of TEP1 with the telomerase RNA and the TERT subunit, the role of TEP1 in the
telomerase complex is unknown. Deficiency of TEP1 does not seem to result in an
alteration of telomerase activity or telomere length, as was shown in TEP1 knockout
mice by Liu et al. (7). These knockout mice also revealed that TEP1 is required for
stability of the vault RNA (vRNA) and its association with the vault particle (8). The
193 MiVP, called VPARP has a functional poly(ADP-ribose) polymerase domain
and is capable of ADP-ribosylating itself and MVP. No other substrates have been
identified yet. The vault RNA constitutes less than 5% of the particle mass. In
humans three different vRNAs have been identified. A fourth homologous sequence
was found, but was shown not to be expressed in various human cell lines (9, 10). In
rat and mouse only one vRNA gene was found (11).
The vault complex is a barrel-shaped structure, that in a three-dimensional image
reconstruction seems to be hollow (12). Diverse species appear to have vault
structures of similar size and morphology, which suggest that this highly conserved
shape of the vault particle is important for its function (2). The role of vaults within
the cell is still unknown, but several functions for the complex have been proposed
in the literature. Although most of the vaults are located in the cytoplasm, some
studies describe an association of the vault complex with the nucleus, in particular
the nucleolus and nuclear pore complex (13, 14). Vaults may therefore be involved
in intracellular transport, in particular nucleocytoplasmic transport of e.g. ribosomes
or mRNA molecules (14) and/or steroid hormone receptors (15).
There is much evidence that links vaults to cellular detoxification processes and
multidrug resistance (MDR); MVP and other vault components are upregulated in P-
glycoprotein (MDR1) independent multidrug resistant tumor cells (9, 16, 17) and
MVP was found to be an indicator of MDR in various human cancer cell lines (18).
Furthermore, Kitazono et al. suggested that vaults operate in MDR by inhibiting or
blocking the accumulation of anthracyclins in the cell nucleus (19, 20). The exact
molecular mechanism by which vaults function in MDR however, remains unclear.
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To investigate the role of vaults in multidrug resistance we started the generation of
a MVP knockout mouse model. To that end, we isolated and characterized the
murine MVP  cDNA and genomic sequence. We determined the intron-exon
structure and functionally analyzed part of the promoter area of the murine MVP.
Furthermore we compared our data with the human MVP gene and MVP proteins
from different species.
Materials and Methods
Cloning and sequencing of the murine MVP cDNA
Total RNA was extracted from the mouse leukemic cell line DA24 (21) using
guanidinium isothiocyanate (22). 2.5 µg of total RNA was used as template in a
reverse transcriptase reaction containing 160 ng of random hexamers (Pharmacia
Biotech, Uppsala, Sweden), 0.3 mM of each dNTP, 3.3 mM DTT, 20 U RNAsin
(Promega, Madison, WI), 1 x first strand buffer and 200 U Superscript (Life
Technologies Inc., Gaithersburg, MD) in a total volume of 30 µl. The largest part of
the mouse MVP cDNA was amplified by PCR, using primers based on rat and
human MVP sequences. The forward primer was 5’ CAACTGAAGAKKC-
CATCATCCGCA and the reverse primer was 5’ KGATTTCAGGCCCAGG-
GAGTG. PCR conditions were as follows: 94°C for 2 min, 33 cycles of 94°C 50
sec, 58°C 1 min, 68°C 3 min, and finally 68°C 10 min, using the Taq/Pwo
polymerase mixture and buffer from the ExpandTM kit (Roche, Mannheim, FRG). A
single PCR product of approximately 2.5-kb was cloned into the pCRT MII TA
cloning vector (Invitrogen, Carlsbad, CA). The 5’ and 3’ ends of the cDNA were
cloned from DA24 total RNA by RACE protocols using 5’/3’ RACE kit (Roche,
Mannheim, FRG). The following sequence primers were used: 5’
GGAYGTGCAGTCAGTGGAGCC, 5’ CCAAGCAYGAGGCTCAGAGAC for the
3’ RACE and for the 5’ RACE: 5’ GATCACAGCGTCCACCAGATC and 5’
CACTCCTCACCTGTCACCCGT. A set of plasmids with nested deletions was
generated by exonuclease III and S1 nuclease (Erase a Base kit, Promega, Madison,
WI) and used to sequence both strands.
Cloning of the murine MVP gene
A genomic library of the mouse strain 129/Ola, constructed in Escherichia coli
(strain LE 392) using partially Sau3A-digested DNA ligated into λEMBL-3, was
provided by Dr. D.N. Meijer (Dept. of Cell Biology and Genetics, Erasmus
University Rotterdam). The genomic library was screened for recombinant clones
containing the murine MVP according to standard protocols (22) by hybridization
with a radiolabeled probe consisting of a 184-bp fragment derived from the 5’ end of
the murine MVP cDNA (nucleotide 108 – 292). Overnight hybridization was carried
out in Church buffer (23) at 65°C. Posthybridization washes were carried out for 20
min. at 65°C in 6 x SSC, 0.1% SDS; 3 x SSC, 0.1% SDS, 1 x SSC, 0.1% SDS
subsequently. Positive plaques on duplicate filters were selected and rescreened.
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High-titer phage lysates were prepared and the recombinant phage DNA was
isolated as described (22). In a second library screen a 683-bp fragment derived
from the 3’ end of the MVP cDNA (nucleotide 2120-2803) was used as a probe in
order to clone genomic fragments encompassing the 3’ end of the gene.
Restriction mapping and sequence analysis of the murine MVP gene
A physical map was constructed from the cloned genomic inserts. Appropriate
restriction enzyme fragments were subcloned into pBSKSII (Stratagene, La Jolla,
CA). Fragments containing MVP exons were identified by Southern blotting (see
section 2.5) using the complete MVP cDNA as probe. Hybridizing fragments were
sequenced using multiple primers based on the cDNA sequence.
Cloning of the murine MVP promoter
Upstream sequences containing putative promoter elements were cloned by genome
walking essentially as described by Shyamala and Ames (24) with the following
modifications: Genomic DNA derived from the embryonic stem cell line E14 was
digested with SacI and the resulting fragments were cloned into the SacI site of
pBSKSII (Stratagene, Inc., La Jolla, CA). The ligation reactions contained 190
µg/ml of vector and variable (0.6 – 6 µg/ml) amounts of E14 DNA fragments in a
total volume of 10 µl. 1.5 µl of each ligation reaction was used as a template in a
PCR using the ExpandTM High Fidelity PCR System (Roche, Mannheim, Germany)
and a vector specific primer (5’-GTAAAACGACGGCCAGTGAGC) and a gene
specific primer located in intron 1 (5’-GGGCAGACATCTACTCCCGGGTTGG).
Sequences upstream of the untranslated exon 1 were PCR amplified using a second,
nested, exon 1 specific primer (5’-GGTCAGGAATTTCCCTCACCAAC) as well as
a nested vector primer (5’-GTAATACGACTCACTATAGGGCG). The PCR
conditions were 95°C, 3 min; then 5 cycles of 95°C, 30 sec; 50°C, 45 sec; 68°C, 3
min; then 20 cycles of 95°C, 30 sec; 50°C, 45 sec; 68°C, 4 min; then 5 cycles of
95°C, 30 sec; 50°C, 45 sec; 68°C, 5 min followed by 68°C, 5 min. A single PCR
fragment of 449 bp was cloned into pCR-Blunt (Invitrogen, Carlsbad, CA) and
sequenced.
Southern blotting
Genomic DNA was digested with appropriate enzymes and separated on a 0.8%
agarose gel as described by Sambrook et al. (22). Subsequently, the DNA was
transferred to Hybond N+ filter (Amersham Pharmacia Biotech, Uppsala, Sweden) in
10 x SSC as transfer buffer. The DNA was cross-linked to the filter by incubation at
80°C for two hours and pre-hybridized in Church buffer (23) at 65°C for 60 minutes.
A 2481 bp fragment of the murine MVP cDNA (nucleotide 108-2589) was
radiolabeled and used as probe. Hybridization was performed in Church buffer at
65°C overnight. Subsequently, the blots were washed with 2 x SSC at 65°C for 20
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min and exposed to a Kodak X-omatTMAR film (Kodak, Rochester, NY) or to a
Phosphorimager screen (Molecular Dynamics, Sunnyvale, CA).
Promoter activity assay
To test if the cloned region upstream MVP exon 1 indeed displayed promoter
activity, we generated two constructs, using the following primers: A forward
primer forw(5’-GAGCTCCAGGACAGC) 378 bp upstream exon 1, a reverse primer
within exon 1 rev1(5’-GGTCAGGAATTTCCCTCAC) and a reverse primer just
downstream of exon 1 rev2(5’-GTCCCGCCACGGTC). The resulting PCR
fragments of 421 and 485 bp were cloned in the TA cloning vector (Invitrogen,
Carlsbad, CA) and subsequently cloned into the pGL3-Basic vector Luciferase
Assay System (Promega, Madison, WI), both in sense and anti-sense direction,
resulting in vectors pGL3-promMVP421s, pGL3-promMVP421as, pGL3-
promMVP485s and pGL3-promMVP485as. The obtained vectors and negative
control vector were transfected into 3T3 fibroblasts using the CaPO4 precipitation
transfection method. In short: cells were seeded in a 6-wells plate (Costar, Corning
Inc., Corning, NY) in low density so that 24 hours later the wells were 50-75%
confluent. 10 µg of DNA was mixed with 250 µl of 0.25 M CaCl2. Subsequently,
250 µl HEBS buffer (274 mM NaCl, 10 mM KCl, 1.4 mM Na2PO4, 1 mM glucose,
42 mM Hepes, pH 7.05) was added drop wise while vortexing. The mixture was left
at RT for 15 min, then carefully added to the cells. 1.25 µg of a β-galactosidase
expressing vector pCH110 (25) was co-transfected. After 24 hours, the cells were
lysed using 50 µl of lysis buffer (25 mM Tris phosphate pH 7.8, 15% glycerol, 1%
Triton X-100 and 1 mM DTT, with freshly added 8 mM MgCl2). Half of the cell
lysate was transferred to a 96-well flat bottom assay plate (Costar, Corning Inc.,
Corning, NY) and to each well, 25 µl of a 16 mg/ml Luciferase substrate containing
buffer (Steady-Glo luciferase assay System, Promega) was added. The emitted light
was measured in a TopCount luminometer (Packard). The remaining 25 µl of cell
lysis material was transferred to a flat bottom 96-well plate (Costar, Corning Inc.,
Corning, NY) and incubated with 75 µl β-galactosidase substrate buffer containing
100 mM sodium phosphate buffer pH 7.8, 10 mM KCl, 1 mM MgSO4, 2.7 mM DTT
and 0.56 mg/ml ONPG (o-nitrophenyl β-D-galactopyranoside, Sigma) at 37°C
during 1-6 hours. Produced yellow staining was measured in a microplate reader
(Model 450, Biorad) at 450 nm. Luciferase activity levels were corrected for
transfection efficiency using β-galactosidase expression levels.
Results and Discussion
Murine MVP closely resembles other MVPs
The full-length cDNA of 2823 bp encoding the murine major vault protein was
cloned by performing several subsequent RT-PCR steps. The sequence is available
at Genbank (AF210456). Sequence analysis revealed an open reading frame of 2610
bp coding for a protein of 870 amino acids with a calculated molecular mass of 96.8
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kDa. However, downstream of the putative translation start position 77-79, another
potential start site is present at position 104-106 consistent with the situation found
in rat MVP cDNA, as described by Kickhoefer and Rome (26). This second ATG
most likely functions as the translational start-site because, together with its flanking
sequences, it fits the consensus for an optimal start site (27). The use of this ATG as
start codon results in a protein of 861 amino acids and a calculated mass of 95.8 kDa
(amino acid sequence not shown). Alignment of the murine MVP amino acid
sequence with other MVP sequences present in the database reveals a high degree of
conservation. As expected, the mouse sequence most closely resembles other
mammalian sequences having an overall identity of 95% and 91% with rat and
human respectively (Table 1). The identity with MVPs from lower eukaryotes is still
considerable (52%-68%).
Table 1. Percentages of overall amino acid identity between major vault proteins from
several organisms.
Mouse Rat Human T. Marmorata I. punctatus D. discA D. discB
MmMVP -
RnMVP 95 -
HsMVP 91 87 -
TmMVP 68 68 68 -
IpMVP 65 65 67 65 -
DdMVPA 56 56 57 55 55 -
DdMVPB 52 52 52 51 50 60 -
MeMVP 58 58 58 60 64 56 49
The presented percentages are calculated using the clustal W program (31). Abbreviations:
MmMVP (Mus musculus MVP/AF210456); RnMVP (Rattus norvegicus MVP/U09870)
HsMVP (Homo sapiens MVP/X79882); TmMVP (Torpedo marmorata MVP/X87771);
IpMVP (Ictalurus punctatus MVP/AAG00866); DdMVPA (Dictyostelium discoideum MVP
A/L08646); DdMVPB (D. discoideum MVP B/Z37109); MeMVP (Mytilus edulis
MVP/AF172605).
The genomic structure of murine MVP
About 2 x 106 plaques of the 129/Ola-strain genomic phage library were screened
using a 184-bp 5’ probe (nucleotide 108-292 of the murine MVP cDNA). Of the
positive clones, one was selected and purified (EMBL3-F). The isolated DNA was
analyzed by restriction mapping and Southern analysis. This revealed that the
genomic insert of 15 kb contained approximately 65% of the 5’ MVP coding
sequence. A second screening of the library was performed using a newly designed
probe of 683 bp (nucleotide 2120-2803) to isolate the 3’ remainder of the gene. One
positive clone was isolated and purified and characterized by restriction mapping
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(EMBL3-H). Comparison of the restriction maps of the two clones indicated that the
genomic inserts overlap and together cover about 17 kb of continuous genomic
DNA (Figure 1A).
Figure 1. Physical map and intron-exon structure of the murine MVP gene. A) Physical
map of subcloned fragments EMBL3-F (5’ clone) and EMBL3-H (3’ clone). Indicated are the
following restriction sites: B, BamHI; E, EcoRI; S, SacI. B) Schematic view of the genomic
organization of the murine MVP gene showing sizes of introns and exons. Exons are depicted
as black boxes. The size of the intron between exon 1 and 2 is unknown, but is at least 2.5 kb.
Exact sizes of introns and exons are given in Table 2.
Southern blotting experiments in which genomic DNA, digested with the
appropriate restriction enzymes, was hybridized with a MVP cDNA probe of 2500
bp confirm that the sizes of the hybridizing bands match with the sizes predicted by
the restriction map of the genomic stretch (data not shown). Low-stringency washes
of similar Southern blots do not suggest the presence of additional similar MVP
genes in the murine genome. This finding was supported by the fact that in an EST
database search no ESTs were found that displayed an identity of less than 95% with
the murine MVP cDNA (data not shown).
E S B S S S E BS
E S SB
EMBL3-F
EMBL3-H
1 Kb
A
B
1 8 923 10 11 12134 5 14 156 7
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To determine the intron-exon structure of the gene, appropriate restriction fragments
were subcloned. The subclones were then analyzed by more detailed restriction
mapping and DNA sequencing, using primers based on the cDNA sequence. Exons
2 to 15 were found in a genomic region spanning 17 kb, localized on chromosome 7.
All of the splice donor and acceptor sites are conform the GT---AG rule for
nucleotides immediately flanking the exon borders (28). A schematic drawing of the
genomic structure of murine MVP gene is given in Figure 1B. In our λ phage library
clones the first untranslated exon was missing. However, part of the intron upstream
exon 2, spanning over 2.5 kb, was sequenced. Sizes of introns and exons are shown
in Table 2. The sequence has been submitted to Genbank (AY046318).
Table 2. Sizes of exons and introns of the murine MVP gene and human MVP exons.
Intron Exon H. Exon
cagcccaTTAGGGAAGT-exon1—-CCTGCTAAATgtgagta 76 44
caatcagGTTAGGCCGG-exon2—-ACAARGAGAGgttggtg >2500 150 160/201a
acaacagGGTACTGTTT-exon3—-GCTGGAAAAGgtacctt 123 196 196
cctgcagGACATCACCC-exon4—-GAGGGACCTGgtgagtc 2950 124 124
tccccagGCACCTACAT-exon5—-CGGGTGACAGgtgggaa 114 132 132
gacccagGTGAGGAGTG-exon6—-TACAGAAAAGgtttgtg 1925 95 95
cctgcagACGGCCCTGC-exon7—-TGTTGTCAAGgtaaggc 264 237 237
ccactagGGAGAGAAGT-exon8--GACGGGAAAGgtacccg 1930 282 282
cccctagGTGCGGGCTG-exon9—-AGAGAGCCCGgtgagcc 722 245 245
tccacagTGTGGTCTTT-exon10-CTTACAACTGgtgaggc 80 198 198
ttcacagGCACTTTGAA-exon11-CAGCAGCCAAgtgagtg 2346 387 387
tacccagGCACGAGGCT-exon12-AGGCGATGAGgtgggtc 602 117 117
cccgcagCATGGCTGTG-exon13-CATTGAGACGgtaagtg 380 127 127
tttccagGAGGCTGAGC-exon14-AGAGATGCAGgtgagaa 651 189 189
cctgcagGTGAAACTTC-exon15-CTGTAAAGAA 365 252 259
a For the human gene alternative splice products have been described (29, 30). Exon
sequences are shown in bold capitals. Sizes are given in basepairs.
Recently, a splice variant of the human MVP was described (29, 30). An alternative
splice acceptor site at the 3’ end of the first intron results in a longer MVP transcript
with an additional open reading frame upstream the initiation start codon. Holzmann
et al. showed that both longer (L-MVP) and shorter (S-MVP) mRNA isoforms are
present at almost constant levels in normal human tissue and that the extra open
reading frame results in a repression of MVP translation. In contrast, in malignant
tissues the ratio of L-MVP versus S-MVP mRNA was found to be more variable,
suggesting that MVP  has a complex posttranscriptional regulation. In mouse
however, the 11 ESTs overlapping the exons 1 and 2 are all identical, practically
excluding the possibility of an alternative splice variant. Our 5’RACE experiments
also did not show any indications for alternative splicing in this area. Thus, the
alternative splice variant L-MVP may influence MVP expression levels in human
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tissues, but as this mechanism is not detected in mouse, this does not seem to be a
highly conserved mechanism for MVP expression regulation.
          forw
MmMVP -378 ----GAGCTCCAGGACAGCCAGGGCTACACAGAAACCCTGTCTCGAAA----AACCAAAA
HsMVP -453 GAGAGAG-TGTGTGAGTGTGTGTTTTCTATTGAACACCTATTCAGAGACCTGGACTGAAT
MmMVP -326 -----------AAAAAAAAAGATGCCGGGTGATCTTCTC---AGAGGAGAGACTGCAGCT
HsMVP -394 TTTCTGAGTCTGAAATAAAAGATGCAGAGCTATCATCTCTTAAAAGGAGGGGCTGTAGCT
MmMVP -280 -CAACCCAAGCACGCATTCTCACTTG--GGCAGAGGCAGAGCTGTGTTCCTCCACACTGT
HsMVP -334 GTAGCTCAACAGTTAGGCCCCACTTGAAGGGAGAGGCAGAATTGTACTCACCCAGATTGG
MmMVP -223 AATATTGAAGCCAGAAGAGGCAGAGG----CTCAGCCAGCCACCATCCCCCACCCCCACC
HsMVP -274 AAAATGAAAGCCAGATG-GGTAGAGGTGCCCTCAGTTAGC-ACC-TGTCCCATCTCGGGC
MmMVP -167 CTTACTGCTGCATCCTCTGATTTCCTAGTCTCGGTCCAGACCCGCCAGTTAGCACTGATT
HsMVP -217 CCTCCAACTCC-----------TCCCAGTCCCACTCCAGTGCAGCCAGCTGGCTCCAAGG
MmMVP -107 CAGAAACT-----GCCCCCAG----CTGTGGTGACTTCAGT----------GCAGCCTGG
HsMVP -168 TAGAAACCCATGAGCACTCAGGGAGCAGTG-TGCCTTCAGCTGCAGCAGAAGCAGCCCGG
MmMVP  -66 AGGAGCAAA--AGATCCAGTTGCA---GGGCCCTTTAAATACACAAGCTCCGCCCCTG--
HsMVP -109 AGGATAAAATGAGAACCAGCTGCACACGGGCCCTTTAACT-CCCAAGCCCCACCCCTGGG
                             •-----------------------------------------
MmMVP  -13 -----CCTGCCCAGCCCATTAGGGAAGTCATCCCAAGTGTTGG-TGAGGGAAATTCCTGA
HsMVP  -50 CTTGGCCTGCCTTGCCCTGCCGGGAAGTGATCCCCAAGGCAGGGTGAGAG---TTCCCCA
                                                                •------
            rev1
           -------------------------------------
MmMVP  +42 CCTGTGGC--CTGCAGCAGCCAGCTACCCTGCTAAATGTGAGTACGGATCTTGTGACCGT
HsMVP   +8 TCTGAGGCGTTTGTTGCAGCTACCTGCACTTCTAGATGTGAGTACA----TTGT-AC--T
           -------------------------------------
rev2
MmMVP +100 GGCGGGACCCCCAA
HsMVP  +61 AGC----CCCCCA-
Figure 2. Clustal W alignment of promoter regions of mouse (MmMVP) and human
(HsMVP) major vault protein gene. Black boxes highlight identical nucleotides. The
untranslated exon 1 is indicated with a dashed line either above (MmMVP) or below
(HsMVP) the sequence. Dots indicate transcription start sites (position +1). The sequence
presented downstream of exon 1 comprises the 5’end of intron 1. Arrows give localization
and direction of oligonucleotides used to generate the promoter constructs examined in this
study. The human promoter sequence (-453 to +69) is as published by Lange et al. (29).
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Functional characterization of the MVP promoter region
A fragment of 449 bp, containing part of exon 1 and upstream sequences, was
isolated by genome walking, cloned and sequenced (Figure 2). The sequence was
submitted to Genbank (AF466399). The obtained potential promoter region was
tested in a promoter activity assay. Using the primers shown in Figure 2, we
generated a pGL3 luciferase vector containing part of the first exon and 378 bp
upstream (pGL3-promMVP421s). Since the untranslated exon 1 might contain
regulatory sequences, a second construct was made, in which both the 378 basepairs
upstream exon 1, the complete exon 1 and 31 bp of the first intron were cloned into
the luciferase vector (pGL3-promMVP485s). As controls, both fragments were
cloned in the antisense direction (pGL3-promMVP421as and pGL3-
promMVP485as). 3T3 cells were transfected with these four constructs and the
empty control plasmid. A β-galactosidase expressing vector was co-transfected to
allow correction for transfection efficiency. Representative results on basal promoter
activity in the luciferase reporter assay are shown in Figure 3.
Figure 3. MVP promoter activity in 3T3 cells. Two luciferase reporter constructs and their
anti-sense variants were generated in the pGL3basic vector. pGL3-promMVP421s and pGL3-
promMVP421as contain putative MVP promoter sequences upstream of the untranslated
exon 1 and part of exon1 in the sense or antisense orientation, respectively. The pGL3-
promMVP485s and pGL3-promMVP485as constructs are similar but encompass the
complete exon 1 and 31 bp of the 5’end of intron 1 in sense or anti-sense orientation,
respectively. The MVP promoter activity was measured in a luciferase assay and normalized
for variations in transfection efficiency using a ß-galactosidase expressing control plasmid.
Depicted are promoter activity values as compared to the luciferase activity of the pGL3basic
vector without an insert, which was arbitrarily set at one. Shown is a representative
experiment, error bars indicate 2 x S.D. (n =8).
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We found that, compared with the empty vector and antisense plasmids, the
construct containing the region directly upstream of exon 1 and part of exon 1 (-378
to +43) displayed promoter activity. Transfection of the larger construct consistently
resulted in even higher luciferase activity levels. This finding suggests that the
untranslated exon 1 or the 5’ end of the first intron play a role in the transcription or
post-transcriptional regulation of murine MVP.
Conservation of MVP
The amino acid identity between human and murine MVP was shown to be 91%.
MVPs from other species, even lower eukaryotes like the slime mold Dictyostelium
discoideum also showed a high degree of similarity. Apparently, MVP has been
particularly well conserved throughout evolution, suggesting a critical function for
this protein and perhaps the vault complex.
In this report we presented the genomic organization of the murine MVP gene.
Comparison of this gene structure with the human MVP gene also shows a high
degree of similarity. Our experiments revealed that the murine MVP gene consists of
15 exons. The same number of exons was reported for the human MVP (29). By
comparing the genomic and cDNA sequence, we determined the sizes of these
exons, which are shown in Table 2. Except for exon 1, 2 and 15, the murine exons
are identical in size to the human exons.
A 1.9 kb genomic fragment directly upstream the human MVP gene was cloned and
tested for promoter activity in a CAT assay. Especially the 700 bp upstream the first
exon were shown to display promoter activity (29). Comparison of this human
promoter sequence and our isolated 449 bp fragment revealed a sequence identity of
58% (Figure 2). Although a suggested regulation of expression of the human MVP
involving alternative splicing was not found to be conserved in the murine gene, the
high degree of similarity between both fragments might imply the presence of
conserved promoter elements and a similar transcriptional regulation of MVP in
humans and mice. Possible binding sites for transcription factors which were
identified in the human sequence (29) do not seem to be conserved in the murine
promoter with the possible exception of the MyoD site (at position -238 to -229 in
the human sequence). However, Figure 2 shows several boxes displaying full
identity between human and murine sequence promoter region. These regions could
be the starting point for a more close experimental examination to identify
transcription factors, and their DNA binding sites, that are important in the
regulation of both murine and human MVP.
In conclusion, MVP displays a high conservation throughout evolution. At least
between the human and murine MVP, this conservation was also observed on a
genomic level and possibly for potential regulatory elements. The information on the
genomic structure of the murine MVP that we have gathered, will allow us to
develop a gene targeting strategy, which can be used in the generation of a MVP
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knockout mouse. A MVP deficient mouse model will hopefully enable us to reveal
the function of MVP and the vault complex in the nearby future.
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Abstract
Vaults are ribonucleoprotein particles with a distinct structure and a high degree of
conservation between species. Although no function has been assigned to the
complex yet, there is some evidence for a role of vaults in multidrug resistance
(MDR). To confirm a direct relation between vaults and MDR and to investigate
possible other functions of vaults, we have generated a major vault protein (MVP)
knockout mouse model. The MVP -/- mice are viable, healthy and show no
abnormalities. We investigated the sensitivity of MVP-/- embryonic stem (ES) cells
and bone marrow cells derived from the MVP deficient mice to various cytostatic
agents with different mechanisms of action. Neither the MVP-/- ES cells nor the
MVP-/- bone marrow cells showed an increased sensitivity to any of the examined
drugs, as compared to wild-type cells. Furthermore, the activities of the ABC-
transporters P-gp, MRP1 and BCRP were unaltered upon MVP disruption in these
cells. In addition, MVP wild-type and deficient mice were treated with the
anthracycline doxorubicin. Both groups of mice responded similarly to the
doxorubicin treatment. Our results suggest that MVP/vaults are not directly involved
in the resistance to cytostatic agents.
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Introduction
The 13 MDa mammalian vault complex is the largest ribonucleoprotein particle
described to date (1). Vaults are predominantly found in the cytoplasm, however, a
small percentage of the vaults seems to be associated with the nucleus, in particular
the nuclear membrane and nuclear pore complex (2-4). Some groups have shown a
partial association of vaults with cytoskeletal elements (4, 5). Although the function
of vaults remains to be elucidated, the subcellular localization of the complex as well
as the distinctive shape, a conserved hollow barrel-like structure with an invaginated
waist and two protruding caps (6), has led people to suggest a function in cellular
transport (7) and/or nucleo-cytoplasmic transport (2-4).
Many reports point to a role of vaults in cellular defense against toxic compounds
and consequently in multidrug resistance (MDR). Relatively high vault levels have
been found in tissues that are frequently exposed to xenobiotic elements, such as
epithelia of the gastro-intestinal tract and lung. Furthermore, the expression of the
major vault protein (MVP), also referred to as lung resistance-related protein (LRP),
was associated with a non-P-glycoprotein mediated multidrug resistant phenotype in
human cancer cell lines (8-11). In addition, MVP expression closely reflected known
chemoresistance characteristics in broad panels of unselected tumor cell lines and
untreated clinical cancers of different histogenetic origins (8, 12). Several clinical
studies indicate that expression of MVP is associated with a poor response to
chemotherapy, but other studies have failed to show a correlation between MVP
expression and clinical drug resistance (for a review see Ref. 13). Direct evidence
for the involvement of vaults in drug resistance was presented by Kitazono et al. (14,
15). They showed that increased levels of MVP in the colon carcinoma SW620 cells
paralleled increased resistance to doxorubicin, etoposide and taxol. This resistance
could be partly overcome by expression of MVP specific ribozymes. However,
expression of MVP, stably transfected in the ovarian carcinoma cell line A2780,
leads to increased numbers of vault particles, but does not confer a drug resistance
phenotype (16, 17).
Vaults consist of three proteins, a 100 kDa major vault protein (MVP) and two
minor vault proteins of 193 kDa (VPARP) and 240 kDa (TEP1), as well as many
copies of a small untranslated RNA (vRNA) of 88-141 bases. Interestingly, the
TEP1 subunit is also associated with the telomerase complex (18, 19). Within this
complex, its function is unknown but it was shown that TEP1 binds to telomerase
RNA (hTR). However, the recently generated TEP1 knockout mice do not show
abnormalities in telomere length nor telomerase activity (20). In these mice, vault-
like particles were observed that appear structurally intact, but have a decreased
density in the caps. It was found that TEP1 is capable of binding vRNA and is
responsible for the stabilization of vRNA and its binding to vaults (21). VPARP
contains a functional poly(ADP-ribose) polymerase (PARP) domain. Several
proteins with such a domain have been identified, PARP1, the best studied protein of
this group, has been shown to play a role in base excision repair. Also other proteins
with PARP activity might be involved in DNA damage repair and genomic stability
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(reviewed in 22). Besides its association with the vault complex, VPARP is also
located in the nucleus, which might point to an involvement in DNA damage repair
as well. VPARP has been shown to ADP-ribosylate itself and MVP (18). The
identification of other substrates of VPARP might give insight in the function of
VPARP and/or the vault complex. The bulk of the vault complex however, is made
up by the major vault protein (MVP). Expression of MVP in insect cells, that do not
express VPARP and TEP1, gives rise to vault-like particles (23), a finding that
illustrates the importance of the major vault protein in the formation of the vault
complex. Absence of MVP will therefore most likely result in a disruption of the
whole vault particle and hence eliminate or severely impair its function.
Here we describe the generation of a major vault protein deficient mouse model.
Previously we revealed the genomic organisation of the murine MVP (24), which
enabled us to construct a targeting vector that was used to disrupt one allele of the
MVP  gene. Subsequently we generated MVP deficient mice that were studied
extensively for any physical abnormalities. In order to investigate the potential role
of vaults in the cellular resistance to chemotherapy, several in vitro drug sensitivity
assays were performed using cells and cell lines derived from the MVP knockout
model. In addition, the in vivo toxicity of doxorubicin was tested in wild-type and
knockout mice to examine the effect of MVP absence on the systemic protection
against chemotherapy.
Materials and Methods
Generation of the targeting construct and MVP deficient Embryonic Stem (ES) cells
The MVP gene was isolated from genomic E14 DNA, and mapped as described (24).
By Southern blot analysis and DNA sequencing the intron-exon structure was
determined. The targeting construct consisted of two genomic fragments, a 2.6 kb
BalI-TthIII1 fragment containing intron 3 and part of exon 4, and a 5 kb EcoRI-SalI
fragment containing exon 8, 9 and 10. These fragments were cloned into pBS-KSII
(Stratagene, La Jolla, CA). Between the two homologous arms we placed a
phosphoglycerate kinase (PGK) driven neomycin cassette, in antisense direction
with respect to the MVP transcription. To facilitate the screen for ES cells that
underwent homologous recombination, the construct was flanked by the negative
selection marker Herpes simplex virus HSV-thymidine kinase (see Figure 1A).
Before electroporation of the ES cells, the vector was linearized by digestion with
NotI. The culturing and manipulation of ES cells were performed essentially as
described before (25). In short: A total of 12 x 106 E14 ES cells, derived from a
129/Ola background, were mixed with 25 µg linearized target vector and
electroporated with a pulse of 117 Volt and 1200 µF for 10 msec. After a 10 min
incubation at RT, the cells were plated in 10 cm2 dishes and incubated at 37°C, 5%
CO2. The following day, the cells were divided over 8 dishes and incubated in G418
and ganciclovir containing medium (300 µg/ml and 100 µg/ml respectively).
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Figure 1. Strategy of MVP gene disruption. A) Schematic presentation of the gene
targeting strategy, showing wild-type allele, targeting construct with the position of the
neomycin resistance and the thymidine kinase cassettes and the recombinant allele after gene
disruption. The dotted line on top indicates the position of the probe used for genotyping
embryonic stem (ES) cell clones and mice. Abbreviations: B; BamHI and S; SalI restriction
enzyme sites. B) Southern blot analysis of wild-type, targeted and double targeted embryonic
stem (ES) cells. BamHI digested genomic DNA was hybridized with the probe depicted in A.
Hybridizing fragments from wild-type (+/+) and MVP knockout (-/-) alleles are 9.8 kb and
3.2 kb, respectively.
A
B
-/- +/+ +/- -/-
9.8 kb
3.2 kb
2 3 4 5 6 7 8 9 10
probe
B S
B
B
B
2 3 8 9 10
B
B
Wildtype allele
Targeting construct
Targeted allele
B
neomycin
4
HSV-TKneomycin
MVP knockout mice and drug sensitivity
50
The clones surviving this selection were isolated, expanded in 24-well plates and
genotyped by Southern blot analysis of BamHI digested DNA, using a 300 bp probe
located just upstream of exon 3 (Figure 1A).
For experimental purposes, the remaining intact MVP allele was also disrupted using
the same targeting construct but with the neomycin cassette replaced by a
hygromycin cassette. Double targeted ES cells were initially selected on a medium
containing hygromycin only (100 µg/ml), and later examined for disruption of both
MVP alleles using the 300 bp probe mentioned above.
Generation and genotyping of MVP knockout mice
Chimeric mice were generated by injecting the manipulated 129/Ola derived, MVP+/-
ES cells into C57BL/6 blastocysts as described (25). Heterozygous offspring of the
chimeric mice was used to generate MVP deficient (MVP-/-), heterozygous (MVP+/-)
and wild-type (MVP+/+) animals. Two sets of primers were used to genotype the
mice by PCR on DNA isolated from tails. One primer set specific for the wild-type
allele (forward 5’-GGCTGGTCCGATCCGTCGGTCCTTATCTCCC and reverse
5’-CAGTAGTGTCGAGGTCCCAGGGTGGTGATG) results in a 520 bp fragment
spanning exon 6 and 7. The second primer set amplifies a 200 bp fragment of the
neomycin cassette (forward 5’-TACTCGGATGGAAGCCGGTC and reverse 5’-
AGTCGATGAATCCAGAAAAG). PCR conditions were: 10 min 94°C, followed
by 30 cycles of 1 min 94°C, 1 min 65°C and 1 min 72°C followed by 10 min at
72°C. The PCR strategy was validated by comparing the results from a Southern blot
analysis with the PCR-based data (data not shown). All animals used in this study
were of a mixed genetic background of 129/Ola and C57BL/6 strains, backcrossed
for 1 to 4 generations to C57BL/6. Littermate wild-type animals were used as
controls, except in the in vivo doxorubicin experiment, where the large numbers of
animals included restricted the use of controls exclusively consisting of littermates.
In this experiment the groups were composed of animals from several litters
matched for age and sex and all derived from fourth generation backcrosses with
C57BL/6.
Western and Northern blot analysis
Tissues from MVP+/+, MVP+/- and MVP-/- littermate animals were homogenized in a
10 mM sodium phosphate buffer (pH 7.4) containing 0.25% (v/v) Triton X-100 and
proteinase inhibitors, using an Ultra-Turrax T25 (IKA-Labortechnik). The tissue
lysates were spun briefly to pellet insoluble material. Protein concentrations were
determined by the BCA method (Pierce, Rochford, Il., USA). MVP was detected
using a polyclonal antibody raised against human MVP (9) and the ECL detection
system (Amersham-Pharmacia, Uppsala, Sweden).
Total RNA was purified from MVP+/+, MVP+/- and MVP-/- littermate animals using
RNAzol (Campro Scientific, Berlin, Germany) following the recommendations of
the manufacturer. 10 µg of total RNA was subjected to formaldehyde-agarose gel
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electrophoresis as described (26). Subsequently the size-fractionated RNA was
blotted onto Hybond-N+ filters (Amersham, Little Chalfont, UK). ULTRAhyb™
(Ambion, Austin, Texas) was used as blocking and hybridization mix according to
the recommendations of the manufacturer. The blot was probed overnight with an in
vitro transcribed antisense [32P]-labeled MVP RNA probe, at 68°C and subsequently
washed for 2 x 5 min in 2 x SSC; 0.1% SDS and 2 x 15 min in 0.1 x SSC; 0.1% SDS
at 68°C. As a loading control, afterwards the same blot was probed with a
radiolabeled 18 S rRNA oligonucleotide probe (5’-CTTTCGCTCTGGTCCGTCTT-
GCGCCGGTCC).
Isolation of immature bone marrow cells
Femurs and tibia were isolated from MVP+/+ and MVP-/- littermates. The bones were
cleaned and crushed in a sterile mortar in order to extract the cells using Hanks
Balanced Salt Solution (HBBS) with 5% Fetal Calf Serum, penicillin (100 units/ml)
and streptomycin (100 mg/ml). The cells were filtered through a 100 mm cell
strainer (Becton Dickinson, Franklin Lakes, NJ, USA) and spun down at 500 x g for
10 min. The cell pellet was resuspended in 50 ml of HBBS and incubated at 37°C
and 5% CO2 for 60 minutes. In order to separate the immature proliferative cells
from the more mature bone marrow cells, the cells were harvested and resuspended
in 300 ml of Ca2+/Mg2+ free PBS and mixed with 2.7 ml of a 55% Percoll
(Amersham-Pharmacia, Uppsala, Sweden) solution. This mixture was loaded on a
Percoll gradient, consisting of 3 ml of 85%, 2 ml of 62% and 2 ml of 55% Percoll in
Ca2+/Mg2+ free HBBS. The gradient was centrifuged 30 minutes at 1650 x g using
slow acceleration and no brakes. The upper fraction, containing the most immature
cells, was collected. In order to induce proliferation, the cells were pre-stimulated in
Cellgro medium (Boehringer, Heidelberg, Germany) containing 10 ng/ml TPO
(Genentech, South San Francisco, CA, USA), 10 ng/ml GM-CSF (R&D,
Minneapolis, MN, USA) 10 ng/ml IL3 (R&D), 100 ng/ml SCF (Amgen, Thousand
Oaks, CA, USA) and 50 ng/ml FLT3 (Immunex, Seattle, WA, USA). After 2 days
the cells were harvested and used in proliferation assays. During the proliferation
assays the cells were cultured in medium containing the growth factors mentioned
above.
Functional tests for P-gp, MRP1 and BCRP
The activities of P-gp, MRP1 and BCRP were monitored by FACS analysis. 3 x 105
wild-type and knockout ES cells or immature bone marrow cells were incubated in
DMEM medium with or without 2 mM of the P-gp inhibitor PSC 833 (Novartis
Pharma) or 100 mM of the MRP1 inhibitor MK571 (Alexis, Lausen, Switzerland) or
with 200 nM of the BCRP modulator Ko143 (27). After a 30-60 min. incubation at
37°C, 5% CO2, 200 ng/ml Rhodamine-123 (Sigma-Aldrich), 100 nM
carboxyfluorescein diacetate (DCFDA) (Sigma-Aldrich) or 100 nM BODIPY-
prazosin (Molecular Probes Inc, Eugene, OR), substrates for P-gp, MRP1 or BCRP
respectively, was added. The cells were incubated with the substrates for an
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additional 75 minutes, after which the cells were mixed with 2 ml of ice-cold PBS
supplemented with 0.1% sodium azide and spun at 650 x g. Before analyzing the
cells by FACS, 8 ml 5 nM TOPRO-3 (Molecular Probes) was added. 8226S and the
P-gp overexpressing derivative 8226D6 (28), GLC4 and the drug resistant derivative
expressing MRP1 and vaults GLC4-ADR (29) and MCF-7 and the drug resistant,
BCRP overexpressing cell line MCF-7 AdVp3000 (30) were included as positive
and negative controls for P-gp, MRP1 and BCRP function, respectively.
Analysis of drug sensitivity
(i) Cell survival assay. The sensitivity to anti-cancer agents was tested in MVP+/+
and MVP-/- ES cells using a MTT microtiter plate assay (31). In brief: On day 1,
3000 cells were seeded in 50 µl medium per well on gelatin coated flat-bottom 96-
well plates. After an incubation of 6 hours at 37°C, 5% CO2, drugs were added at
various concentrations. After 3 days of incubation, 10 µl of a 5 mg/ml methyl thiazol
tetrazoliumsalt (MTT) solution in 0.9% NaCl was added in each well and the
incubation continued for an additional 6 hours at 37°C, 5% CO2. The formazan
crystals produced by viable cells were resuspended by adding 100 µl per well of
acidified isopropanol, after which the absorbance at 562 nm was measured on a plate
reader. At least 12 different drug concentrations were used to determine IC50 values.
(ii) Cell proliferation assay. Proliferation of bone marrow cells from MVP+/+ and
MVP-/- littermate mice was tested in a [3H]-thymidine incorporation assay. For this
purpose, immature bone marrow cells, isolated by means of a Percoll gradient and
pre-stimulated for 48 hours, were seeded at a density of 20.000 cells per well in a
microtiter plate in 100 µl of medium containing growth factors and incubated at
37°C, 5% CO2. Drugs were added 24 hours later, in various concentrations and the
cells were incubated for an additional 8 hours. Then [3H]-thymidine (25 µCi in 25 µl
medium) was added to each well and the cells were incubated overnight. Cells were
transferred to a glass fiber filter using a filtermate 196 cell harvester (Packard
Bioscience, Groningen, The Netherlands) and the radioactivity on the filters was
determined by a topcount microplate scintillation counter (Packard Bioscience).
(iii) In vivo toxicity of doxorubicin. 10 or 15 mg doxorubicin per kg bodyweight was
administered to MVP knockout animals and age and sex matched wild-type animals
by intravenous injection in the tail. The animals were examined daily for signs of
discomfort and illness. Bodyweights were determined daily and blood cell counts
were performed on days 3 and 8 after injection. At day 5 after injection, the animals
that received the 10 mg/kg doxorubicin dose and PBS injected controls, were
sacrificed and examined thoroughly for histopathologic abnormalities using standard
protocols.
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Figure 2. Absence of MVP transcript and protein confirms MVP gene disruption. A)
Northern blot analysis of total RNA from the liver of wild-type (+/+), heterozygous (+/-) and
MVP knockout (-/-) littermates hybridized with a MVP antisense RNA probe. The lower
panel shows the same blot hybridized with a control 18 S rRNA probe. B) Western blot
analysis of protein lysates from several tissues from wild-type (+/+), heterozygous (+/-) and
MVP knockout (-/-) littermates for MVP expression. Equal amounts of protein (40 µg) were
loaded in each lane
Results
MVP deficient mice are viable and appear normal
ES cell clones surviving the selection medium were genotyped by digestion with
BamHI followed by Southern blot analysis. This resulted in a 9.8 kb and a 3.2 kb
hybridizing fragment for the wild-type and recombinant allele, respectively (Figure
1B). A probe at the 5’ end of the construct was used to confirm the disruption of the
MVP allele. The presence of additional integrations was excluded by using a probe
based on the neomycin cassette (results not shown). Before the MVP+/- ES cells were
injected into blastocysts, the number of chromosomes present in metaphase spreads
was counted to verify the karyotype was stable.
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Chimeric animals, resulting from blastocysts injection were backcrossed to C57BL/6
mice, to obtain heterozygous animals. These heterozygous mice were intercrossed to
produce MVP+/+ and MVP-/- littermates. The genotype of the animals was determined
by Southern blot analysis and/or PCR on tail DNA (cf. Figure 1B). The disruption of
MVP was confirmed at RNA and protein level. A Northern blot analysis on total
RNA isolated from liver from wild-type, heterozygous and MVP deficient animals
demonstrated that no MVP  transcripts were detectable in the knockout tissue.
Although the loading was not completely equal, judged from the 18S rRNA signal, a
decreased signal was found in the heterozygous tissue when compared to the normal
tissue (Figure 2A). On Western blot, the knockout tissues contained no detectable
MVP and the heterozygous tissues showed intermediate levels of protein expression
(Figure 2B). Similar results were observed with other organs (data not shown).
The MVP knockout mice appeared viable, were born at Mendelian ratios, bred
normally and did not show clear physical abnormalities up to 16 months of age.
Animals of different age were histologically examined, with special attention to
tissues that normally express relatively high levels of MVP/vaults (i.e. lung, liver
and gastro-intestinal tract). No microscopical differences were observed between
knockout and wild-type littermates (data not shown). Also no differences were
observed in bone marrow and peripheral blood cell counts, and in serum levels of
glucose, blood urea, cholesterol and creatine (results not shown).
Figure 3. Expression of MVP in ES cells and bone marrow. Western blot analysis of
protein lysates from wild-type (+/+) and MVP knockout (-/-) ES cells and bone marrow cells.
Equal amounts of protein were loaded in each lane.
Drug sensitivity in MVP deficient cells
A correlation between vault expression and drug resistance has been shown in cell
lines as well as for primary human tumors. To examine whether vaults influence the
cellular defense against drugs, we tested the sensitivity of ES cells and immature
bone marrow cells to various cytostatic agents. Both ES and immature bone marrow
cells were shown to express MVP, whereas no MVP could be detected in MVP-/- ES
and bone marrow cells derived from MVP-/- mice (Figure 3).
+/+ -/- +/+ -/-
ES cells       BM cells
MVP
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The survival of MVP-/- ES cells in response to increasing concentrations of cytostatic
drugs was compared with the survival of the parental MVP+/+ ES cells in a MTT
assay. To determine the drug concentration at which 50% of the cells survives (IC50
value), 12 different concentrations of each drug were tested. Although a broad range
of drugs, exerting toxicity in different manners, was included, no statistically
significant differences in IC50 values were observed between wild-type and knockout
cells for any of the cytostatics (Table 1).
Table 1. In vitro cytotoxicity of several cytostatics in MVP+/+ and MVP-/- ES cells.
Agent IC50 (ng/ml)
MVP+/+ ES cells MVP-/- ES cells
Doxorubicin 7.28 ± 1.0 6.15 ± 0.77
Doxorubicin + 50 µM MK571 3.6 ± 1.0 4.3 ± 0.5
Etoposide 2.38 ± 0.08 2.0 ± 0.08
Etoposide + 50 µM MK571 1.0 ± 0.08 0.9 ± 0.2
Vincristine 0.86 ± 0.2 0.83 ± 0.053
Methotrexate 11.4 ± 0.58 12.9 ± 2.3
Ifosfamide 466 x 103 ± 87x103 471 x 103 ± 35 x 103
Mitoxantrone 0.53 ± 0.08 0.7 ± 0.2
Gemcitabine 10.05 ± 0.8 10.35 ± 1.1
Taxotere 0.38 ± 0.1 0.30 ± 0.023
Cisplatinum 198 ± 37 228 ± 52
Melphalan 244 ± 71 299 ± 34
Cytosine arabinoside 151 ± 36 244 ± 88
Dexamethason 25 x 103 ± 211 35 x 103 ± 1330
Given are average IC50 values ± S.D. calculated from 2-3 independent experiments (n = 4-6).
Note that some assays were carried out in the presence of 50 µM of the MRP1 inhibitor
MK571. No statistically significant differences were observed between IC50 values in wild-
type and knockout cells as determined by the Mann-Whitney test.
To investigate the effect of drugs on the proliferative capacity of wild-type and
knockout cells, we used immature bone marrow cells, induced to proliferate in a
[3H]-thymidine incorporation assay. The proliferation after a 24 hour incubation with
increasing concentrations of cytostatic agents, was expressed as a percentage of the
proliferation measured in untreated cells. The drug concentrations at which the
proliferation is decreased by 50% are listed in Table 2. In all cases, the inhibition of
cell proliferation induced by the cytostatics appears unaltered in MVP deficient
cells.
To test whether the absence of MVP results in altered expression of other multidrug
resistance related proteins such as P-gp, MRP1 and BCRP, the activities of these
membrane pumps were examined in wild-type and knockout ES cell lines and bone
marrow cells.
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For this purpose, we measured the intracellular retention of fluorescent substrates in
the presence or absence of P-gp, MRP1 and BCRP modulators by flowcytometry.
The ratio of substrate retained in the cell in the presence and absence of their
modulators is a measure of the activity of these membrane pumps. Table 3
summarizes the activities of the three proteins on ES cells and immature bone
marrow cells.
Table 2. Inhibition of proliferation of MVP+/+ and MVP-/- bone marrow cells in response
to several cytostatic agents.
Agent Drug concentration (µg/ml)
MVP+/+ BM cells MVP-/- BM cells
Doxorubicin 0.131 ± 0.026 0.119 ± 0.027
Etoposide 2.73 ± 1.47 2.84 ± 1.47
Vincristine 0.047 ± 0.008 0.055 ± 0.004
Methotrexate 0.046 ± 0.006 0.039 ± 0.0015
Ifosfamide 2423 ± 270 1991 ± 514
Mitoxantrone 0.0073 ± 0.0016 0.0081 ± 0.0021
Gemcitabine 0.029 ± 0.011 0.0183 ± 0.001
Taxotere 0.0058 ± 0.0006 0.0054 ± 0.0004
Cisplatinum 7.06 ± 2.27 6.23 ± 2.48
Melphalan 5.06 ± 1.19 3.93 ± 1.53
Cytosine arabinoside 0.11 ± 0.02 0.11 ± 0.003
Dexamethason 322 ± 36 326 ± 44
Presented are the drug concentrations at which proliferation is reduced to 50% as compared to
untreated cells. Given are average values ± S.D. calculated from 2 independent experiments
(n = 4-6). No statistically significant differences were observed between 50% inhibition
values in wild-type and knockout cells as determined by the Mann-Whitney test.
Table 3. Functional expression of P-gp, MRP1 and BCRP in MVP+/+ and MVP-/- cells.
Bone Marrow ES cells
MVP+/+ MVP-/- MVP+/+ MVP-/-
P-gp 1.45 1.51 1.21 0.95
MRP1 10.41 10.48 7.5 8.8
BCRP 1.34 1.09 1.18 1.15
Depicted are the ratios calculated from the intracellular fluorescent substrates in the absence
and presence of the specific modulators PSC 833, MK571, Ko143. Values given are averages
of 2 independent experiments.
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Figure 4. Functional expression of MDR related proteins in wild-type and MVP
knockout cells. The activities of P-gp, MRP1 and BCRP are presented as the intracellular
amounts of Rhodamine-123 (P-gp substrate), DCFDA (MRP1 substrate) or BODIPY-
prazosin (BCRP substrate) in wild-type (WT) and MVP deficient (KO) embryonic stem (ES)
cells in presence (grey plot) or absence (black plot) of the modulators PSC 833, MK571 and
Ko143 .
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Both ES cells and bone marrow cells appear to exhibit a low activity of P-gp and
BCRP, whereas addition of the MRP1 modulator MK571 clearly increased the
intracellular amount of fluorescent substrate, indicating that MRP1 is functionally
present on the surfaces of these cells (Figure 4). However, the absence of MVP does
not lead to an increased activity in any of the MDR related proteins tested.
To investigate whether the inhibition of MRP1 has more severe consequences for the
MVP knockout cells than for the MVP wild-type cells, the sensitivity to doxorubicin
and etoposide in the presence of the MRP1 modulator MK571 was tested in a MTT
assay. Doxorubicin and etoposide were chosen since these agents are known
substrates of MRP1. Although the IC50 values of both doxorubicin and etoposide
were clearly reduced by adding MRP1 inhibitor (Table 1), this effect was not found
to be more pronounced in the MVP deficient cells.
Toxicity of doxorubicin in vivo
Although the disruption of the MVP gene did not result in an altered sensitivity to
drugs in bone marrow and ES cells, it is possible that MVP/vaults play a role in the
protection of a specific organ. Such an observation was reported for the P-gp
deficient mice, in which absence of P-gp in the blood-brain barrier led to
accumulation of ivermectin in the brain resulting in a 100-fold increased sensitivity
level to this agent (32). We tested the in vivo toxicity of doxorubicin in MVP
knockout mice, since the relation between drug resistance and MVP expression was
most obvious for anthracyclines (14, 15). We examined the general appearance,
weight loss and blood cell numbers of 21 wild-type and 23 knockout mice treated
with a single intravenous doxorubicin injection of 15 mg/kg bodyweight. The MVP
deficient animals did not show increased symptoms of illness and discomfort, when
compared to wild-type control animals. The number of white blood cells was slightly
decreased three days after injection in both groups when compared to non-injected
animals, but had recovered in both wild-type and knockout mice on day 8 (data not
shown). The effects of the doxorubicin treatment on the bodyweights are presented
in Figure 5.
Both MVP+/+ and MVP-/- animals showed loss of weight during the first days after
injection, but the average weight loss was similar in both groups and all animals
were able to stabilize and started to recover their weights. Furthermore, the damage
to organs after injection of 10 mg doxorubicin/kg bodyweight, was investigated
extensively, with special attention to organs that normally exhibit a high expression
of MVP. Effects of the doxorubicin treatment, such as hydropy in the liver and the
disruption of the morphology of the villi in the ileum, were visible in both knockout
and wild-type organs (five wild-type versus five knockout animals), but the levels of
the induced tissue damage were similar (data not shown).
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Figure 5. Effects of doxorubicin treatment on bodyweights of MVP wild-type (WT) and
deficient (KO) mice. Depicted is the average bodyweight ± S. D. of mice intravenously
injected with 15 mg/kg doxorubicin, as percentage of the initial bodyweight before treatment.
Bodyweights were measured daily after injection of doxorubicin. Black diamonds represent
wild-type mice (n = 21), white squares represent knockout mice (n = 23).
Discussion
We have successfully generated a major vault protein knockout mouse. The MVP
mRNA and protein are undetectable in the tissues of the knockout animals and
severely reduced in heterozygous animals. Both the high degree of evolutionary
conservation and the complex structure of vault particles as well as its broad
distribution in tissues suggest an important function in cellular processes.
Surprisingly, the MVP knockout animals do not show any obvious abnormalities,
breed normally and appear healthy. Apparently, vaults do not play an essential role
in the development of mice and in cellular processes in a normal healthy
environment However, vaults could be involved in a strategic mechanism needed for
survival after induction of cellular stress or damage. Since the cellular defense
against cytotoxic agents may partly rely on vaults, as was suggested in several
clinical studies and experiments using MDR cell lines, we have examined a potential
function of vaults in multidrug resistance.
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To this purpose, two different cell types derived from the MVP knockout model,
were tested in two different assays. Firstly, the survival of MVP+/+ and MVP-/- ES
cells, when exposed to different concentrations of cytostatics, was examined in a
MTT assay. Similar experiments have been performed in MRP1 deficient ES cells
by Lorico et al., who observed that disruption of MRP1, a MDR related membrane
transport protein, leads to hypersensitivity to etoposide and teniposide and, to a
lesser extent to doxorubicin. Decreased IC50 values of up to 4-fold were reported
(33). In our experiments, no significant difference in IC50 values, and no difference
in the survival curves of MVP deficient and wild-type ES cells were observed.
Secondly, the effects of cytostatic agents on the proliferative capacity of immature
bone marrow cells isolated from knockout and wild-type littermate animals were
examined in a [3H]-thymidine incorporation assay. The inhibition of proliferation in
response to all administered drugs was similar in wild-type and MVP deficient cells.
Finally, although more extensive research using several cytotoxic agents at different
concentrations should be performed to determine the in vivo sensitivity of the MVP
knockout mice, the systemic protection to doxorubicin seems unaltered in MVP
deficient mice as compared to the wild-type control mice. Siva et al. suggested that
vaults may be necessary, though not sufficient for drug resistance (17). The data
presented in this study confirm these findings and even suggest that MVP and vaults
are not necessary for the resistance to a broad range of anticancer drugs.
In contrast, in a number of cell line models, MVP expression has been found to
correlate with resistance to several cytostatic agents. A clear relation between MVP
expression levels and resistance to doxorubicin, etoposide, taxol and vincristine was
reported by Kitazono et al. (14, 15). Colon cancer SW-620 cells with induced MVP
expression were 6-fold more resistant to doxorubicin, 9-fold to etoposide, 8-fold to
taxol and 2-fold to vincristine, as determined by a MTT assay. When MVP transcript
levels were decreased by the expression of MVP specific ribozymes, the cells lost
the acquired resistance. A mechanism for the action of MVP/vaults proposed by the
authors, is the efflux of doxorubicin from the nucleus. However, since not all drugs
investigated in their study have nuclear targets, this only explains part of the
acquired resistance of the SW-620 cells. The results of these studies also imply that
by losing MVP, cells become more susceptible to doxorubicin, etoposide and taxol.
However, the MVP deficient ES and bone marrow cells used in our study were not
more susceptible to these cytostatic agents, or to any other agent tested.
A possible explanation for the unexpected lack of a drug sensitive phenotype in the
MVP deficient mice is that vaults only contribute moderately to drug resistance and
that the absence of MVP is compensated for by other MDR proteins, like ABC-
transporters such as P-gp, MRP family members or BCRP. However, in the MVP
deficient cell systems used in this study, no increase of activity of P-gp, MRP1 and
BCRP was observed. A functional assay showed a considerable activity of MRP1 in
both ES cells and bone marrow cells, but this activity did not change after disruption
of MVP. Addition of a MRP1 inhibitor indeed increased the susceptibility of ES
cells for the MRP1 substrates, doxorubicin and etoposide, but the effects were
Chapter 3
61
identical in MVP wild-type and deficient cells. Hence, it is not likely that the effects
of the disruption of MVP are compensated for by P-gp, MRP1 or BCRP. However, it
can not be excluded that other ABC-transporters or unknown mechanisms of drug
resistance become upregulated upon disruption of MVP . Furthermore, our
experiments did not include long term exposure of cells to low doses of cytostatic
agents. Although a direct involvement of vaults in MDR could not be demonstrated
in the MVP knockout mouse model, vaults might still be involved in the protection
against chronic exposure to drugs. On the other hand, the upregulation of MVP that
has been described in both in vitro and clinical studies, might be a response to
cytostatics, but not directly related to the resistance to these agents. Vaults may be
involved in other cellular processes that also become activated upon exposure to
toxic agents, such as apoptosis and/or a general stress response. In addition, some
evidence for a role of vaults in cellular differentiation was given by Schroeijers et
al.. The observed upregulation of vaults during the development of dendritic cells
and the impaired function of dendritic cells treated with antibodies against MVP
suggest that vaults play a role in the development, maturation and functioning of
dendritic cells (34). We are currently investigating the development and antigen
presenting capacity of dendritic cells derived from the MVP knockout mice.
Although the major component of the vault particle is absent, the remaining
components TEP1, VPARP and vRNA might still interact and possibly fulfil a
functional role. However, the levels of the additional vault components seem to be
severely reduced in MVP knockout tissues (See Chapter 4). Besides the vault-
associated fractions of TEP1 and VPARP, also their levels outside the vault
complex, i. e. associated with the telomerase complex and the nuclear portion of
VPARP, may be affected by the disruption of MVP. If this is the case this might
indicate a functional link between vaults and the telomerase complex in addition to
the simple sharing of the TEP1 subunit. Likewise a possible function of nuclear
VPARP in DNA damage repair might also be impaired. Determination of the levels
of the minor vault proteins, their subcellular localization and the mechanism
responsible for the decrease in their concentrations upon MVP disruption could give
important clues on the still unrevealed function of the vault complex.
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Abstract
Vaults are large ribonucleoprotein particles of unknown function. The complex
consists of three proteins, MVP, TEP1 and VPARP and small untranslated vault
RNAs. MVP is the main structural component and responsible for the formation of
the particles. MVP knockout mice are viable and show no clear abnormalities. In this
paper we demonstrate that vault particles are absent in MVP knockout tissues.
Moreover, western blot analysis of MVP-/- tissues, ES and MEF cells revealed that
TEP1 and VPARP protein levels are severely decreased. The levels and half-life of
vRNA were also found to be reduced, probably due to the decrease in TEP1 levels.
Northern blot analysis showed that TEP1 and VPARP mRNA levels and polysome
formation are unaffected, suggesting that the reduction of TEP1 and VPARP are
caused by protein instability. Re-introduction of GFP-tagged MVP in MVP-/- MEF
cells resulted in vault particle formation and increased levels of VPARP protein and
vRNA. MVP molecules with a deleted coiled-coil domain could not form vault
particles, nor restore VPARP and vRNA levels. These data suggest that the
formation of vault particles is mediated by the coiled-coil domain of MVP and is
essential for stabilization of the other vault components.
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Introduction
Vaults are large ribonucleoprotein particles of unknown function, found in most
eukaryotic cells. The majority of vaults reside in the cytoplasm, but a small fraction
of around 5% is constitutively found associated with the nucleus (1-3). The complex
consists of three different proteins and multiple copies of one or more small
untranslated RNA molecules. The most abundant protein, called the major vault
protein (MVP), is approximately 100 kDa and makes up 70% of the total mass of the
complex. The other protein constituents are the 193 kDa vault poly(ADP-ribosyl)
polymerase, VPARP, and the 240 kDa telomerase/vault associated protein 1, TEP1,
referred to as minor vault proteins (MiVP). Not all TEP1 and VPARP in the cell are
associated with the vault complex. It is not clear whether these proteins fulfil
separate functions, unrelated to the function of vaults, in their non-vault associated
forms. VPARP has been detected in non vault-associated cytoplasmic clusters and is
also present in the nucleus (4). TEP1 is shared with another ribonucleoprotein
complex, namely the telomerase complex. The function of TEP1 in the telomerase
complex is not yet known, but it has been shown that TEP1 is capable of binding the
telomerase RNA (TR) and immuno-precipitates of TEP1 contain associated
telomerase activity (5). Similarly, TEP1 can bind vault RNAs (6). The vault RNA
(vRNA) differs slightly in size between species. In human cells, three different,
highly homologous vRNAs, hvg1, hvg2 and hvg3 are expressed, that are 98, 88 and
88 bases in size, respectively (7, 8). Rodents only express one larger vRNA, of 141
bases (7-9). The RNA component accounts for about 5% of the mass of the total
particle and is not believed to be a structural component of the vault complex but
rather a functional one, since degradation of vRNA does not alter vault morphology
(10-13).
The vault complex is 35 x 65 nm in size and has an estimated molecular mass of
approximately 13 MDa (14), making it the largest ribonucleoprotein complex
known, in fact three times the size of a ribosomal subunit. The vault proteins are
arranged in a typical hollow barrel-like structure with an 8-2-2 symmetry, an
invaginated waist and two protruding caps (11, 15). MVP has been shown to be
responsible for the vault morphology, as in the absence of minor vault proteins it is
capable of forming particles that closely resemble intact vault particles (16). TEP1,
vRNA and probably VPARP are localized in the caps of the vault particle (11, 12).
A model has been proposed in which an intact vault complex contains 96 copies of
MVP, and 2 molecules of TEP1, 8 molecules of VPARP and 16 copies of vRNA
(11). The characteristic morphology of the vault particle is conserved between
species, suggesting it is relevant for vault functioning (17). However, so far this
function remains an enigma. Based on vault morphology, subcellular localization
and dynamics, several groups have suggested a role for vaults in cellular transport
(1-3, 18, 19). Since the lung resistance-related protein (LRP) was identified as the
major vault protein (20), studies have also focussed on the involvement of vaults in
detoxification and multidrug resistance, possibly by the transport or sequestration of
drugs, for a review see Scheffer et al. (21).
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TEP1 knockout mice are viable and show no apparent abnormalities (12, 13). In
these animals, telomerase activity and telomere length appear normal. In addition the
level of the telomerase RNA and its association with the telomerase complex are
unaltered (12). However, the half-life of vRNA is severely reduced in the TEP1
knockout mice, and vRNA no longer stably associates with vaults. No major
structural changes in purified vaults, isolated from TEP1-/- tissues, were observed
and the levels of MVP and VPARP are comparable in the TEP1 knockout and wild-
type mice.
Deletion of MVP probably has severe consequences for the integrity of the vault
complex, and its associated components. Despite the conservation of vaults in
mammals, the MVP  knockout mice are viable, fertile and have no apparent
abnormalities or increased sensitivity to cytotoxic chemicals (22). This lack of
phenotype could be explained by a redundancy for MVP, as was the case in
Dictyostelium discoideum where three homologues of MVP have been identified (23,
24). However, the murine genome does not contain additional genes with high
similarity to MVP (25).
Here we demonstrate that in the absence of MVP, vault particles are no longer
formed and that the steady-state levels of TEP1, VPARP and vRNA are severely
reduced in MVP-deficient mouse tissues and cells. Furthermore, we show that TEP1
and VPARP mRNA levels and polysome formation are not affected upon loss of
MVP suggesting that their reduced levels are due to a decrease in protein stability.
Re-introduction of full-length MVP in knockout cells restored the levels of VPARP
and vRNA, whereas truncated MVP, in which part of the coiled-coil domain is
deleted, could not restore VPARP nor vRNA levels. These data suggest that MVP
and in particular its coiled-coil domain, is required for vault particle formation and
stabilization of VPARP, TEP1 and vRNA.
Materials and Methods
Generation of MVP Deficient Mice and Embryonic Stem Cells
Homozygous MVP-/- mice and embryonic stem (ES) cells were generated as
described previously (22). The mice used in this study are of a mixed genetic
background (C57BL/6 and 129/OLA), backcrossed on C57BL/6 for 3 to 5
generations.
Mouse Embryonic Fibroblasts (MEFs) isolation and culture conditions
13.5 days old embryos were isolated from extra-embryonic membranes and heads,
hearts and livers were removed. The remaining parts of the embryos were
transferred to a 10 cm2 dish, chopped into small pieces to which 2.5 ml of MEF
medium (50% DMEM, 50% Ham’s F10 supplemented with 10% FCS, 100 units/ml
penicillin, 100 µg/ml streptomycin and 2 mM L-glutamin) was added. Every 24
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hours, 2.5 ml of fresh medium was added till a maximum volume of 12.5 ml was
reached. The cells were cultured at 37°C in a humidified atmosphere containing 5%
CO2. Established MEF cell lines were obtained by keeping the primary cells nearly
confluent and trypsinizing weekly, until spontaneously immortalized cells,
overcoming senescence could be selected.
Vault purification and analysis
Vaults were purified from ~ 7 grams of mouse liver as described previously (15),
using a protocol adapted to the limited quantities of the mouse livers (12). In the
final purification step, the vaults were purified over a single cesium chloride
gradient to get rid of ferritin, which is the major contaminant during vault
purification from tissue. Vaults were recovered from several gradient fractions by
dilution and pelleting at 100.000 x g using a Ti80 rotor (Beckman Coulter) and
resuspension in 75 µl of 90 mM MES, pH 6.5 containing 1 mM DTT, 0.5 mM
PMSF and a protease inhibitor cocktail. Of each fraction, 20 µl was subjected to
SDS-PAGE, followed by either silver staining or immuno-blot analysis using anti-
(MVP), anti-(VPARP) and anti-(TEP1) antibodies previously described (4, 6).
Electron microscopical analysis of uranyl acetate stained vaults was performed as
described (10).
SDS-PAGE and immuno-blotting
Fresh tissues from MVP+/+, MVP+/- and MVP-/- littermate animals were homogenized
in a 10 mM sodium phosphate buffer (pH 7.4) containing 0.25% (v/v) Triton X-100
and protease inhibitors CompleteTM (Roche Applied Science, Mannheim, Germany),
using an Ultra-Turrax T25 homogenizer (IKA-Labortechnik). The tissue lysates
were spun briefly to pellet insoluble materials. Embryonic fibroblasts and ES cells
were lysed in the same solution. Protein concentrations were determined by the BCA
method (Pierce, Rochford, IL). Cell lysates were subjected to SDS-PAGE and the
size-fractionated proteins transferred to nitrocellulose. The protein blots were
blocked in TBST (50 mM Tris-Cl pH 7.5, 100 mM NaCl, 0.05% (v/v) Tween 20)
containing 5% (w/v) non-fat dry milk (Bio-Rad, Laboratories, Hercules, CA). MVP
was detected using a rabbit polyclonal antiserum raised against human MVP that
cross-reacted with murine MVP (26). VPARP was detected using the mouse mAb
p193-10 recognizing an epitope conserved between mouse and human (26). TEP1
was detected using an affinity purified rabbit anti-(TEP1) polyclonal antiserum
obtained from Dr. L. Harrington, (University of Toronto, Canada). Species-specific
anti-Ig antibodies conjugated to horseradish peroxidase (Jackson ImmunoResearch
Laboratories, Westgrove, PA) were used as second antibody. Immune-complexes
were detected using the BM chemiluminescence kit (Roche Molecular
Biochemicals, Mannheim, Germany) and visualized on Hyperfilm ECL (Amersham-
Pharmacia, Uppsala, Sweden). Western blotting results were quantified using
ImageQuaNT, (Molecular Dynamics, Sunnyvale, CA).
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Northern blot analysis
Total RNA was purified from fresh tissues from MVP+/+, MVP +/- and MVP-/-
littermate animals using RNAzol (Campro Scientific, Veenendaal, The Netherlands)
following the recommendations of the manufacturer. Total RNA from cell lines was
isolated using the RNAeasy kit (Qiagen, Hilden, Germany). 10 µg of total RNA was
subjected to formaldehyde-agarose gel electrophoresis essentially as described (27).
Subsequently the size fractionated RNA was blotted onto Hybond-N+ filters
(Amersham, Little Chalfont, UK). ULTRAhyb™ (Ambion, Austin, Texas) was used
as blocking and hybridization solution according to the protocol supplied by the
manufacturer. Radiolabeled anti-sense RNA probes were prepared by in vitro
transcription using T7 or Sp6 RNA polymerase from the following linearized
templates: the murine MVP cDNA (nucleotide position 108 – 2589) cloned in
pCR2.1 (Invitrogen, Carlsbad, CA); the myc-tagged murine TEP1 cDNA cloned in
pCR3 (myc3-mTP1) obtained from Dr. L Harrington (University of Toronto,
Canada) and a ~2000 bp fragment of the murine VPARP gene, which was PCR
amplified from cDNA prepared from total murine liver RNA and cloned in pCR-
Blunt (Invitrogen, Carlsbad, CA). The oligonucleotides used were based on mouse
ESTs that displayed a high similarity with human VPARP cDNA; forward primer
5’CTTGCAGATATTTAGAGTTGGCAGAG T G  a n d  r e v er se  p r imer
5’CCAGTTGTCTTCTGAAGCTCAGTAG. After hybridization, the blots were
washed 2 x 5 min in 2 x SSC; 0.1% SDS and 2 x 15 min in 0.1 x SCC; 0.1% SDS at
68°C. Northern blot analysis of vRNA, using a universal vRNA probe, was
performed as described before (7). Afterwards, the blots were stripped and reprobed
with a 5 S rRNA probe as a control for equal loading. For the half-life determination
of vRNA, cells were incubated with 10 µg/ml actinomycin D. Samples for RNA
isolation, using RNAzol were taken at 0, 30 min, 1, 2, 3, 4, 6 and 8 hours. Northern
blotting results were quantified using ImageQuaNT, (Molecular Dynamics,
Sunnyvale, CA).
Fractionation of polysomal bound RNA
Sucrose gradients were prepared in 5 ml Ultraclear polystyrene ultracentrifuge tubes
(Beckmann Coulter, Mijdrecht, The Netherlands) as follows: 1 ml 40% (w/v)
sucrose, 1 ml 31.6% sucrose, 1 ml 23.3% sucrose and 1 ml 15% sucrose. Before
adding each new layer, the tubes were snap frozen in liquid nitrogen. The gradients
were stored at –80°C and thawed slowly (overnight at 4°C) before use. All sucrose
solutions contained 10 mM DTT, 100 µg/ml cycloheximide and 500 µg/ml heparin.
Around 25 x 106 wild-type and MVP-/- ES cells were harvested and resuspended in
400 µl NP-40 buffer (0.5% (v/v) NP-40 in 10 mM Tris-HCl pH 7.5, 140 mM NaCl,
1.5 mM MgCl2, before use, 12 µ l of 40 U/µl RNAsin, 15 µ l of 10 mg/ml
cycloheximide, 20 µl 1M DTT and protease inhibitors were added to 943 µl NP-40
buffer). The cell lysates were resuspended by pippeting up and down 10 times and
spun for 3 min at 3300 x g to remove the nuclei. The supernatants were transferred
to a new RNase free tube and 30 µl heparin (50 mg/ml) was added. Mitochondria
and membrane particles were removed by centrifugation at 13.000 x g at 4ºC for 10
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minutes. The supernatants were loaded onto the sucrose gradients, which were
centrifuged at 4ºC for 1 hour at 42.000 rpm in a SW50Ti rotor (Beckmann).
Afterwards, the gradient was aliquotted in 550-600 µl fractions that were transferred
to tubes containing 58 µl 10% SDS, 12 µl 0.5 M EDTA pH 8.0 and 10 µl proteinase
K (10 mg/ml) and mixed immediately. After an incubation of 30 min at 37ºC, 750 µl
phenol:chloroform (1:1) was added, the tubes were vortexed for 1 min and spun at
13.000 x g for 5 min at room temperature. The water phase was transferred to a fresh
tube and an equal volume of isopropanol was added and the RNA was allowed to
precipitate for at least 1 hour at –20ºC. After spinning at 13.000 x g for 30 min, the
pellets were washed with 75% EtOH and air dried for 10 min. The RNA pellet was
dissolved in 15 µl DEPC-treated water, of which 2 µl was used in a Northern blot
analysis to detect TEP1 and VPARP transcripts.
Retroviral gene transfer
The following N-terminal GFP-tagged constructs were cloned into the pBabePuro
vector (28): human full-length MVP (GFP-MVP1-893) and a truncated human MVP
deleting the coiled-coil domain (GFP-∆MVP1-706). For the production of virus,
PhoenixE cells (Dr. G. Nolan, Stanford University, CA) were seeded at a density of
2.5 x 106 cells/10 cm2 dish in 10 ml DMEM medium supplemented with 10% FCS,
100 units/ml penicillin and 100 µg/ml streptomycin. After an overnight incubation at
37ºC, in a humidified atmosphere containing 5% CO2, the cells were transfected
with 10 µg DNA of the appropriate constructs, by the CaPO4 precipitation method.
After 24 hours, the medium was replaced and again 24 hours later, the virus
containing supernatant was harvested, filtered through a 0.45 µm filter, snap frozen
in liquid nitrogen and stored at –80ºC. For the infection of the MEFs, 3.5 cm2 dishes
were coated with 12 µg retronectine in 1 ml PBS for 2 hours. The retronectine
solution was removed and the dishes were incubated with 1 ml 2% (w/v) BSA in
PBS for 30 min. After washing the dishes twice with PBS, they were pre-treated
with 1 ml virus supernatant, for 1 hour at 37ºC. 0.2 x 106 embryonic fibroblasts in 1
ml MEF medium were mixed with 1 ml virus supernatant and seeded in the pre-
treated dishes. After 24 hours at 37ºC, 1 ml medium was removed and replaced with
fresh virus supernatant. After an additional 24 hours at 37ºC, the cells were washed
twice in PBS and incubated in selection medium, containing 2.5 µg/ml puromycine.
Surviving clones were amplified and the percentage of transfected cells expressing
the GFP tagged MVP constructs was estimated by FACS analysis.
Cell fractionation
Between 30-60 x 106 wild-type MEF cells, MVP-/- MEF cells and MVP-/- MEF cells
expressing the GFP-tagged MVP constructs (see retroviral gene transfer, this
section) were lysed in vault-buffer (50 mM Tris-Cl, pH 7.4, 1.5 mM MgCl2, 75 mM
NaCl and 0.5% (v/v) NP-40), supplemented with a cocktail of protease inhibitors
CompleteTM (Roche Applied Science, Mannheim, Germany). Nuclei were removed
by centrifugation at 13.000 x g and the supernatant was diluted to a final volume of 5
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ml with vault-buffer. After centrifugation at 100.000 x g at 4°C, the pellet was
resuspended in 1 ml vault-buffer, and applied to sucrose gradients and centrifuged as
described before (8). After centrifugation, the sucrose gradients were aliquotted into
10 fractions, which were analyzed by Western blotting
Fluorescence microscopy
Cells were grown on poly-L-lysine coated coverslips, fixed with 3% (v/v)
formaldehyde in PBS for 20 minutes at room temperature and permeabilized by 5
minute incubation in a 1% (v/v) Triton-X100 solution in PBS. Coverslips were
mounted on microscope slides in anti-fade (4% (w/v) n-propyl gallate in glycerol).
The fluorescent pattern was examined using a Leica DMRXA microscope and
pictures were created using Leica QFish version V 2.3e.
Results
MVP disruption results in the absence of vault particles
Because MVP is the main structural vault protein, it was expected that its absence
would result in disruption of the vault complex. To confirm this, we attempted to
isolate vaults from livers of both wild-type and MVP knockout mice using the
standard vault purification procedure involving differential centrifugation steps as
well as velocity sucrose gradient centrifugation. In the final purification step, vaults
were loaded on a cesium chloride gradient in order to separate vaults from ferritin, a
major contaminant. Four fractions normally containing the partially purified vault
particles were isolated from both wild-type and MVP knockout livers. Subsequently,
these purified vault fractions were subjected to SDS-PAGE. Figure 1A shows the
silver stained gel. In the wild-type fractions the vault proteins MVP, TEP1 and
VPARP are clearly visible. In the corresponding MVP-/- fractions, as expected no
MVP was detected, however, TEP1 and VPARP were also undetectable. The fact
that equal amounts and similar sized contaminating proteins were present in both
wild-type and MVP-/- fractions indicate that the fractions were indeed comparable.
These results were confirmed in immuno-blotting experiments (Figure 1B) and
indicate the absence of a particle with the physical-chemical properties of vaults in
MVP knockout livers and imply that there is no other protein substituting for MVP
to make a vault particle. Electron micrographs of the wild-type fraction 3 show
distinct particles with the typical lobular vault morphology, while the corresponding
fraction, as well as the other fractions, derived from MVP-/- livers were devoid of
these particles (Figure 1C).
BC
MVP -/- MVP +/+
MVP -/-
1 2 3 4
MVP +/+
1 2 3 4
MVP
TEP1
VPARP
MVP -/-
1 2 3 4
MVP +/+
1 2 3 4
MVP
TEP1
VPARP
A
Chapter 4
73
Figure 1. Absence of vault particles in MVP knockout mice. A) Livers from wild-type
(+/+) and MVP knockout (-/-) mice were used to partially purify vault particles as described
in the Materials and Methods. In the final purification step, the vaults were purified over a
single cesium chloride gradient. Vaults were recovered from the gradient in four fractions by
dilution and subsequent pelleting at 100.000 x g. The fractions (1-4) were analyzed by SDS-
PAGE and the proteins present visualized by silver staining. Protein bands corresponding to
vault proteins are marked in wild-type fractions and were not detected in MVP-/- fractions,
whereas contaminating proteins where present in both liver preparations in about equal
amounts. B) The presence of vault proteins in the wild-type fractions and their absence in
MVP-/- fractions were confirmed by immuno-blotting. C) All wild-type and MVP knockout
fractions were analyzed by electron microscopy. Vault particles with the typical barrel-shaped
morphology could easily be detected in the wild-type liver fractions, but were completely
absent in the corresponding fractions of the MVP knockout livers. Shown are electron
micrographs of negatively stained vault preparations that were obtained from wild-type and
knockout fraction 3. Scale bars correspond to 50 nm.
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The absence of MVP affects the levels of the other vault components
Since in the absence of MVP no vault particles appear to be formed, as a
consequence potential vault functions that utilize the typical barrel-shaped
morphology most likely are also abolished in these cells. However, the minor vault
proteins and/or vRNA may still be functional, either in the context of each other or
in vault-independent processes. We therefore investigated the levels of TEP1,
VPARP and vRNA in MVP knockout tissues and compared these with the levels
observed in tissues from heterozygous and wild-type mice. Liver, lung and colon
were selected since vaults are highly expressed in these tissues.
The absence of MVP appeared to have unexpectedly strong effects on the steady-
state levels of the remaining vault proteins. Figure 2A indicates that the levels of
both TEP1 and VPARP were severely reduced in all tissues examined. In colon,
which normally shows the highest levels of TEP1 and VPARP, this reduction was
most obvious and was determined to be over 50-fold for both proteins. In lung and
liver from the knockout mice, the levels of these proteins were even below detection
level in this particular experiment. Interestingly, the disruption of a single MVP
allele in the heterozygous tissues led to a 2-6 fold reduction in TEP1 and VPARP
levels as compared to wild-type levels. The level of VPARP in the MVP+/- lung did
not seem to be reduced, but this lane was slightly overloaded, as was determined by
the PonceauS staining (not shown). We next investigated the levels of the vault
proteins in MVP knockout cell-lines, e.g. the embryonic stem (ES) cells and mouse
embryonic fibroblasts (MEFs). We consistently observed a decrease of VPARP
levels upon MVP disruption in protein lysates from ES and MEF cell lines (Figure
2B). It was noted that the VPARP reduction in the cell lines is less pronounced (3-6
fold) than what we observed in the tissues. Unfortunately the anti-TEP1 antiserum,
cross-reacted with several high molecular weight proteins in the protein lysates of
the ES and MEF cells obscuring the TEP1 signals, therefore no conclusion could be
reached directly on TEP1 levels in these lines.
We next examined vRNA levels in the same MVP knockout tissues as used above.
The Northern blot analysis is shown in Figure 2C. The vRNA levels were decreased
2- to 3-fold in these tissues upon MVP disruption, and intermediate levels were
observed in tissues from heterozygous mice. To determine the half-life of vRNA in
the MVP  knockout cells, MEFs were incubated with actinomycin D to inhibit
transcription. Total RNA was isolated before the addition of actinomycin D and at
30 min, 1, 2, 3, 4, 6 and 8 hours after addition (Figure 2D). In the wild-type MEFs,
the half-life of vRNA was calculated to be around 4 hours, whereas this was reduced
to 1.5-2 hours in the MVP deficient cells. Most probably, the decrease in vRNA
stability is caused by the reduction of TEP1 protein levels. It has previously been
shown that TEP1 is essential for the stabilization of vRNA and its association with
the vault complex. In the absence of TEP1, vRNA levels are decreased 3- to 5-fold
and vRNA half-life is reduced to 0.5-1 hour (12). The decreased vRNA levels and
half-life in the MVP-deficient MEFs suggest that TEP1 levels are also reduced in
these cells.
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Figure 2. Levels of TEP1, VPARP and vRNA are severely reduced in the absence of
MVP. A) Protein lysates, corresponding to 50 µg of total protein from MVP+/+, MVP+/- and
MVP-/- tissues were subjected to SDS-PAGE and immuno-blotting to detect the steady-state
levels of MVP, VPARP and TEP1. Lung, liver and colon were investigated since these
tissues normally contain relatively high levels of vaults. Upon disruption of MVP, the levels
of both minor vault proteins are severely reduced. Loss of a single MVP allele, in the MVP+/-
tissues already results in markedly reduced levels of TEP1 and VPARP. B) Protein lysates,
corresponding to 50 µg of total protein from MVP+/+ and MVP-/- MEF and ES cells were
subjected to SDS-PAGE and immuno-blotting to detect MVP and VPARP levels. C)
Northern blot analysis showing the levels of vRNA in wild-type, heterozygous and MVP
knockout tissues. 15 µg of total RNA, isolated from various tissues was loaded in each lane.
Levels of vRNA were determined by hybridization with a vRNA oligonucleotide probe as
described in Materials and Methods. D) Determination of the half-life of vRNA in wild-type
and MVP knockout MEFs. Cells were incubated with actinomycin D to inhibit transcription
and RNA samples for Northern blot analysis were taken after 30 min, 1, 2, 3, 4, 6 and 8
hours. vRNA Northern blots were stripped and re-probed with a 5 S rRNA probe as a loading
control.
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MVP determines the stability of the minor vault proteins
The decreased levels of TEP1 and VPARP in MVP knockout cells and tissues can
result from several causes, such as a reduction in transcription or translation rate.
Alternatively, the absence of MVP might alter the instability of TEP1 and VPARP
mRNA and/or proteins. Siva et al. presented evidence that over-expression of MVP
in the transfected A2780 cell line AC16 resulted in increased levels of TEP1 and
VPARP mRNA and proteins (29). In order to investigate whether the loss of MVP
affects the steady state levels of TEP1 and VPARP mRNA, total RNA was purified
from the livers of wild-type and MVP  knockout mice and wild-type and MVP
knockout cell lines. As shown in Figure 3A, the mRNA levels of both TEP1 and
VPARP were not reduced in the MVP-/- liver tissue. Similar results were obtained in
cell lines (data not shown). These data indicate that the reduced protein levels of the
minor vault proteins upon MVP disruption are not caused by a transcriptional
downregulation, but must be either brought about at a translational or post-
translational level.
Figure 3. TEP1 and VPARP mRNA levels and polysome formation are unaffected by
the loss of MVP. A) Total RNA was isolated from wild-type and MVP knockout liver
tissues. 10 µg of RNA was subjected to Northern blot analysis and the blots were hybridized
with MVP, TEP1 and VPARP probes. B) To determine the percentage of TEP1 and VPARP
transcripts being translated, total RNA from MVP+/+ and MVP-/- ES cells was fractionated on a
sucrose gradient into subpolysomal and polysomal bound mRNA. The sucrose gradients were
fractionated into 8 equal portions. RNA in each fraction was isolated and analyzed by
Northern blotting to detect the TEP1 and VPARP mRNAs. Fractions 1-3 of the sucrose
gradients correspond to subpolysomal RNA, and fractions 5-8 contain the polysomal bound
RNAs. Fraction 4, containing a mixture of subpolysomal and polysomal RNA is not taken
into account when calculating the distribution of TEP1 and VPARP transcripts.
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To distinguish between these two possibilities, total RNA from wild-type and MVP-/-
ES cells was isolated and fractionated into a subpolysomal and polysomal-bound
fraction, using sedimentation centrifugation on a sucrose gradient (30, 31).
Northern blot analysis was used to determine the localization of TEP1 and VPARP
transcripts in the gradient and to calculate the percentage of transcripts that are
polysome bound, i.e. being translated. Almost all the message from both TEP1 and
VPARP appeared to be in the fractions containing polysomal bound mRNA (fraction
5 to 8), as is seen in Figure 3B. In the wild-type cells, the percentages of polysomal
bound RNA were found to be 96% for TEP1 and 91% for VPARP. These
percentages were similar in the MVP deficient cells (95% for TEP1 and 88% for
VPARP). The high percentages of polysomal bound TEP1 and VPARP transcripts
suggest that the proteins are constitutively produced. Loss of MVP does not seem to
influence the rate of translation of TEP1 and VPARP messages. Thus, the observed
differences in MiVP levels seem to be caused by an increased protein instability.
To investigate whether re-introduction of MVP into MVP knockout cells could
restore the minor vault protein and vRNA levels to wild-type amounts, we cloned a
N-terminal GFP-tagged (human) MVP construct (GFP-MVP1-893) into a retroviral
expression vector pBabe. A construct expressing GFP only was used as a negative
control. After retroviral transduction and selection for transduced cells on
puromycine, the percentage of GFP or GFP-MVP1-893 expressing cells was
determined by FACS analysis (85% for GFP-MVP1-893  and 95% for GFP, results not
shown). The intracellular localization of the GFP-MVP1-893 construct was
determined by microscopical analysis and appears to be identical to the typical
granular cytoplasmic staining that has been described for intact vault particles
(Figure 4A). This suggests that these GFP-MVP molecules are assembled into vault
particles. To confirm these results, a 100.000 x g pellet from wild-type and GFP-
MVP1-893 expressing knockout cells was size-fractionated over a sucrose gradient
(Figure 4B). Although the gradients are not completely identical, the GFP-tagged
MVP molecules were detected in comparable gradient fractions (peaking at 40-45%
sucrose) as the murine MVP in the wild-type cells, indicating that the GFP-tagged
MVP molecules are incorporated into complexes with a mass and size similar to
vault particles. Moreover, in addition to GFP-MVP1-893, these fractions also
contained TEP1 and VPARP, implying the formation of genuine vaults in the GFP-
MVP transfected knockout cells. In Figure 4C, the levels of VPARP and vRNA in
the GFP-MVP1-893 expressing cells are compared with the levels in the wild-type and
MVP deficient cells. Expression of GFP-MVP1-893 restored the VPARP level, which
was found to be 12-fold increased compared to the level detected in the MVP
deficient cells. The restored levels exceeded the levels observed in the wild-type
cells, which may be explained by the relatively high expression level of the GFP-
MVP1-893 construct, calculated to be around 8 times as high as the level of the wild-
type MVP. The vRNA levels are also increased in the MVP  knockout cells
expressing the full-length GFP-tagged MVP construct (2-fold compared to the MVP
deficient cells), indicating that the TEP1 levels are also (partly) restored in these
cells. Apparently, in the formation of the vault complex, MVP is the limiting factor.
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Figure 4. Expression of GFP-MVP in MVP-/- cells stabilizes VPARP and vRNA through
the formation of vault particles. A) GFP-tagged full length human MVP (GFP-MVP1-893)
and GFP-tagged MVP with a partial deletion in the coiled-coil domain (GFP-∆MVP1-706)
were expressed in MVP knockout MEF cells by retroviral gene transfer, as described in
Materials and Methods. The cellular localization of the GFP-tagged constructs was examined
by fluorescence microscopy. B) To examine whether the GFP-tagged constructs are
assembled into vault particles, cell lysates from wild-type and GFP-MVP1-893 expressing
knockout MEFs were prepared and vaults pelleted at 100.000 x g. The pellet was carefully
resuspended and fractionated onto a sucrose step gradient, which was aliquotted into 10
fractions of 1 ml. The presence of MVP, TEP1 and VPARP in these fractions was determined
by subjecting 40 µl of each fraction to Western blot analysis. Vault protein levels were
peaking in wild-type fractions 3 and 4 and in GFP-MVP1-893 fractions 4 and 5, corresponding
to 40-45% sucrose. Note that the TEP1 antibody is useful for detection of TEP1 in the
fractions of the sucrose gradients, whereas the presence of cross-reacting proteins prevent the
use of this antibody to detect TEP1 in total cell lysates. C) The expression levels of MVP and
VPARP protein and vRNA were determined in whole cell lysates from wild-type cells (lane
1), MVP knockout cells (lane 2), GFP-MVP1-893 expressing cells (lane 3) and in GFP-∆MVP1-
706 expressing cells (lane 4). As a negative control, MVP knockout cell expressing GFP were
used (lane 5).
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Complete vault particles are necessary for stabilization of minor vault proteins
Finally, we examined whether VPARP is stabilized and protected from degradation
through its interaction with either single MVP molecules or whole vault particles. To
this end , we generated a GFP-tagged truncated (human) MVP construct with a
partial deletion in the coiled-coil domain (GFP-∆MVP1-706). This domain is
responsible for the interaction between MVP molecules and hence the assembly of
the vault particles (32). Fluorescence microscopy showed that the subcellular
distribution of GFP-∆MVP1-706 is less granular and more diffuse then the full length
GFP-tagged MVP construct (Figure 4A). The GFP-∆MVP1-706 could not be pelleted
at 100.000 x g, indicating that these molecules, lacking the coiled-coil domain, are
not incorporated into vault particles. Hence, no vault proteins could be detected in
the sucrose gradient fractions from the GFP-∆MVP1-706 expressing cells (data not
shown). Note that the region interacting with VPARP was mapped to the N-terminal
part of MVP and is still present in the GFP-∆MVP1-706 molecules (32). However, the
expression of GFP-∆MVP1-706 in the MVP-/- MEFs does not lead to an increase in the
level of VPARP nor vRNA (Figure 4C). These results suggest that the binding of
VPARP to MVP, if it occurs, is not sufficient to stabilize VPARP. Therefore,
incorporation into whole vault particles seems to be essential to stabilize VPARP,
TEP1 and vRNA.
Discussion
Although recently much has been learned about the structure and components of
vaults, the function of this elusive ribonucleoprotein particle remains unknown.
Previously, we reported on the generation of a MVP knockout mouse model (22).
These mice are viable and show no apparent abnormalities. Here we show that loss
of MVP, the main structural component of vaults, has major consequences for the
integrity of the vault particle. In addition, we investigated the effects of the absence
of MVP on the other components of the vault complex.
As expected, the typical barrel-shaped vault particles are absent when MVP  is
disrupted. We have reported that the murine genome, in contrast to Dictyostelium
discoideum, contains only a single copy of the MVP gene (25). The absence of TEP1
and VPARP from “vault” fractions purified from MVP knockout livers indicates that
no other protein(s) are substituting for MVP to form an alternate vault complex. It is
possible that TEP1 and VPARP form a separate complex in the absence of MVP
however, no interaction between these proteins was observed in a yeast two-hybrid
setting (32).
Besides the disruption of the vault complex, loss of MVP strongly affects the levels
of TEP1, VPARP and vRNA. However, in MVP knockout tissues and cell lines the
mRNA levels encoding TEP1 and VPARP remain constant, suggesting that the
transcription and mRNA stability are unaffected. Moreover, since the polysome
profile appears similar in MVP deficient and wild-type cell lines, these results
suggest that the decreased levels of TEP1 and VPARP result from protein instability.
As a consequence of the decreased levels of TEP1 in the MVP knockout tissues, the
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level of vRNA is also reduced. Previously it has been shown that TEP1 is necessary
for vRNA stability (12). The remaining vRNA molecules might also be stabilized by
binding to other factors, such as the La protein, that was recently found to be
associated with vRNA and vaults (33), explaining the still clearly detectable levels
of vRNA even though the level of TEP1 protein is severely reduced. The reduction
of VPARP in cell lines was less dramatic than what we observed in MVP knockout
tissues. This difference may be caused by inherent differences between various in
vitro cell lines and tissues where one might expect that protein degradation pathways
are more active in tissues than in cell lines. Unfortunately, we were not able
determine the TEP1 levels in cell lines due to cross-contaminating proteins
obscuring the TEP1 signal, but the reduced vRNA levels and half-life of vRNA in
the MVP knockout MEFs strongly suggest that TEP1 is also reduced.
In conclusion, in wild-type cells, MVP is required for vault particle formation and
for stabilizing the other vault components. Indeed, when GFP-MVP is expressed in
the knockout MEFs, the VPARP levels are rescued to near wild-type levels.
Interestingly, expression of a truncation mutant lacking the coiled-coil domain in the
C-terminal part of MVP does not rescue VPARP levels. The coiled-coil domain is
thought to have a role in vault particle assembly (32). Therefore it seems likely that
whole vault particles are necessary to prevent degradation of VPARP and probably
TEP1. The resistance of the vault complex against breakdown has been
demonstrated before. Herrmann and colleagues reported that MVP, incorporated in
the complex, is resistant to proteolytic attack (34). Apparently, assembly into the
vault complex is an efficient way of stabilizing the individual components. Based on
the present data one could hypothesize that vaults act to sequester and protect factors
that may interact in a more transient manner. Recently, the tumor suppressor PTEN
has been shown to interact with vaults (35) and several studies have suggested that
vaults play a role as transporters (1-3).
Another possibility is that vaults serve as a storing or stabilizing compartment for
the minor vault proteins, which are otherwise rapidly degraded as determined in this
study. Like the vault particle, the function of the minor vault proteins is not yet
known. Their normal cellular function could be carried out by the non-vault
associated fractions where their activity might be modulated by interaction with
vaults. However, the extreme reduction of TEP1 and VPARP levels in the MVP
deficient mice must also affect the non vault-associated levels of these proteins. The
decrease in TEP1 and VPARP levels in these mice points out the importance of
MVP in the formation of vault particles and in the stabilization of the individual
components. Investigation of the subcellular localization of the remaining TEP1 and
VPARP might shed more light on the function of the vault proteins and the vault
particle.
By disruption of MVP, we have generated the first knockout mouse model in which
genuine vault particles are physically and functionally absent. From our data we
conclude that possible vault functions, utilizing the hollow, barrel-shaped vault
morphology, such as vault-mediated transport, are apparently not essential for
embryonic development, tissue specialization, reproduction or basic essential
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cellular functions.
Acknowledgements
The authors would like to thank Lea Harrington (University of Toronto) for the
rabbit anti-(TEP1) antiserum.
References
1. Abbondanza, C., Rossi, V., Roscigno, A., Gallo, L., Belsito, A., Piluso, G., Medici,
N., Nigro, V., Molinari, A. M., Moncharmont, B., and Puca, G. A. Interaction of
vault particles with estrogen receptor in the MCF-7 breast cancer cell. J Cell Biol,
141: 1301-1310., 1998.
2. Chugani, D. C., Rome, L. H., and Kedersha, N. L. Evidence that vault
ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci, 106: 23-
29., 1993.
3. Hamill, D. R. and Suprenant, K. A. Characterization of the sea urchin major vault
protein: a possible role for vault ribonucleoprotein particles in nucleocytoplasmic
transport. Dev Biol, 190: 117-128., 1997.
4. Kickhoefer, V. A., Siva, A. C., Kedersha, N. L., Inman, E. M., Ruland, C., Streuli,
M., and Rome, L. H. The 193-kD vault protein, VPARP, is a novel poly(ADP-
ribose) polymerase. J Cell Biol, 146: 917-928., 1999.
5. Harrington, L., McPhail, T., Mar, V., Zhou, W., Oulton, R., Bass, M. B., Arruda, I.,
and Robinson, M. O. A mammalian telomerase-associated protein. Science, 275:
973-977., 1997.
6. Kickhoefer, V. A., Stephen, A. G., Harrington, L., Robinson, M. O., and Rome, L.
H. Vaults and telomerase share a common subunit, TEP1. J Biol Chem, 274: 32712-
32717., 1999.
7. van Zon, A., Mossink, M. H., Schoester, M., Scheffer, G. L., Scheper, R. J.,
Sonneveld, P., and Wiemer, E. A. Multiple human vault RNAs. Expression and
association with the vault complex. J Biol Chem, 276: 37715-37721., 2001.
8. Kickhoefer, V. A., Rajavel, K. S., Scheffer, G. L., Dalton, W. S., Scheper, R. J., and
Rome, L. H. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol
Chem, 273: 8971-8974., 1998.
9. Kickhoefer, V. A., Searles, R. P., Kedersha, N. L., Garber, M. E., Johnson, D. L.,
and Rome, L. H. Vault ribonucleoprotein particles from rat and bullfrog contain a
related small RNA that is transcribed by RNA polymerase III. J Biol Chem, 268:
7868-7873., 1993.
10. Kedersha, N. L. and Rome, L. H. Isolation and characterization of a novel
ribonucleoprotein particle: large structures contain a single species of small RNA. J
Cell Biol, 103: 699-709., 1986.
11. Kong, L. B., Siva, A. C., Kickhoefer, V. A., Rome, L. H., and Stewart, P. L. RNA
location and modeling of a WD40 repeat domain within the vault. Rna, 6: 890-900,
2000.
12. Kickhoefer, V. A., Liu, Y., Kong, L. B., Snow, B. E., Stewart, P. L., Harrington, L.,
and Rome, L. H. The Telomerase/vault-associated protein TEP1 is required for
vault RNA stability and its association with the vault particle. J Cell Biol, 152: 157-
Minor Vault Proteins in absence of MVP
82
164., 2001.
13. Liu, Y., Snow, B. E., Hande, M. P., Baerlocher, G., Kickhoefer, V. A., Yeung, D.,
Wakeham, A., Itie, A., Siderovski, D. P., Lansdorp, P. M., Robinson, M. O., and
Harrington, L. Telomerase-associated protein TEP1 is not essential for telomerase
activity or telomere length maintenance in vivo. Mol Cell Biol, 20: 8178-8184.,
2000.
14. Kedersha, N. L., Heuser, J. E., Chugani, D. C., and Rome, L. H. Vaults. III. Vault
ribonucleoprotein particles open into flower-like structures with octagonal
symmetry. J Cell Biol, 112: 225-235., 1991.
15. Kong, L. B., Siva, A. C., Rome, L. H., and Stewart, P. L. Structure of the vault, a
ubiquitous cellular component. Structure Fold Des, 7: 371-379., 1999.
16. Stephen, A. G., Raval-Fernandes, S., Huynh, T., Torres, M., Kickhoefer, V. A., and
Rome, L. H. Assembly of vault-like particles in insect cells expressing only the
major vault protein. J Biol Chem, 276: 23217-23220., 2001.
17. Kedersha, N. L., Miquel, M. C., Bittner, D., and Rome, L. H. Vaults. II.
Ribonucleoprotein structures are highly conserved among higher and lower
eukaryotes. J Cell Biol, 110: 895-901., 1990.
18. Herrmann, C., Golkaramnay, E., Inman, E., Rome, L., and Volknandt, W.
Recombinant major vault protein is targeted to neuritic tips of PC12 cells. J Cell
Biol, 144: 1163-1172., 1999.
19. Li, J. Y., Volknandt, W., Dahlstrom, A., Herrmann, C., Blasi, J., Das, B., and
Zimmermann, H. Axonal transport of ribonucleoprotein particles (vaults).
Neuroscience, 91: 1055-1065, 1999.
20. Scheffer, G. L., Wijngaard, P. L., Flens, M. J., Izquierdo, M. A., Slovak, M. L.,
Pinedo, H. M., Meijer, C. J., Clevers, H. C., and Scheper, R. J. The drug resistance-
related protein LRP is the human major vault protein. Nat Med, 1: 578-582., 1995.
21. Scheffer, G. L., Schroeijers, A. B., Izquierdo, M. A., Wiemer, E. A., and Scheper,
R. J. Lung resistance-related protein/major vault protein and vaults in multidrug-
resistant cancer. Curr Opin Oncol, 12: 550-556., 2000.
22. Mossink, M. H., van Zon, A., Fränzel-Luiten, E., Schoester, M., Kickhoefer, V. A.,
Scheffer, G. L., Scheper, R. J., Sonneveld, P., and Wiemer, E. A. C. Disruption of
the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to
cytostatics. Cancer Res, in press.
23. Vasu, S. K., Kedersha, N. L., and Rome, L. H. cDNA cloning and disruption of the
major vault protein alpha gene (mvpA) in Dictyostelium discoideum. J Biol Chem,
268: 15356-15360., 1993.
24. Vasu, S. K. and Rome, L. H. Dictyostelium vaults: disruption of the major proteins
reveals growth and morphological defects and uncovers a new associated protein. J
Biol Chem, 270: 16588-16594., 1995.
25. Mossink, M., van Zon, A., Franzel-Luiten, E., Schoester, M., Scheffer, G., Scheper,
R., Sonneveld, P., and Wiemer, E. The genomic sequence of the murine major vault
protein and its promoter. Gene, 294: 225-232, 2002.
26. Schroeijers, A. B., Siva, A. C., Scheffer, G. L., de Jong, M. C., Bolick, S. C.,
Dukers, D. F., Slootstra, J. W., Meloen, R. H., Wiemer, E., Kickhoefer, V. A.,
Rome, L. H., and Scheper, R. J. The Mr 193,000 vault protein is up-regulated in
multidrug-resistant cancer cell lines. Cancer Res, 60: 1104-1110., 2000.
27. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: a laboratory
manual, 2 edition. Cold Spring Harbor Laboratory Press, NY, 1989.
28. Morgenstern, J. P. and Land, H. Advanced mammalian gene transfer: high titre
retroviral vectors with multiple drug selection markers and a complementary helper-
Chapter 4
83
free packaging cell line. Nucleic Acids Res, 18: 3587-3596, 1990.
29. Siva, A. C., Raval-Fernandes, S., Stephen, A. G., LaFemina, M. J., Scheper, R. J.,
Kickhoefer, V. A., and Rome, L. H. Up-regulation of vaults may be necessary but
not sufficient for multidrug resistance. Int J Cancer, 92: 195-202., 2001.
30. Garcia-Sanz, J. A., Mikulits, W., Livingstone, A., Lefkovits, I., and Mullner, E. W.
Translational control: a general mechanism for gene regulation during T cell
activation. Faseb J, 12: 299-306, 1998.
31. Mullner, E. W. and Garcia-Sanz, J. A. Polysome gradients. In: I. Lefkovits (ed.),
Manual of immunological methods, Vol. 1, pp. 457-462. London: Academic Press,
1997.
32. van Zon, A., Mossink, M. H., Schoester, M., Scheffer, G. L., Scheper, R. J.,
Sonneveld, P., and Wiemer, E. A. Structural domains of vault proteins: a role for the
coiled coil domain in vault assembly. Biochem Biophys Res Commun, 291: 535-
541, 2002.
33. Kickhoefer, V. A., Poderycki, M. J., Chan, E. K., and Rome, L. H. The La RNA
binding protein interacts with the vault RNA and is a vault-associated protein. J Biol
Chem, 277 : 41282-41286, 2002.
34. Herrmann, C., Volknandt, W., Wittich, B., Kellner, R., and Zimmermann, H. The
major vault protein (MVP100) is contained in cholinergic nerve terminals of electric
ray electric organ. J Biol Chem, 271: 13908-13915, 1996.
35. Yu, Z., Fotouhi-Ardakani, N., Wu, L., Maoui, M., Wang, S., Banville, D., and Shen,
S. H. PTEN Associates with the Vault Particles in HeLa Cells. J Biol Chem, 277:
40247-40252, 2002.

Chapter 5
Unimpaired Dendritic Cell functions in MVP knockout
mice
Marieke H. Mossink, Jan de Groot, Arend van Zon, Erna Fränzel-Luiten,
Martijn Schoester, George L. Scheffer, Pieter Sonneveld, Rik J. Scheper
and Erik A. C. Wiemer.
Submitted
Dendritic cells in MVP knockout mice
86
Abstract
Dendritic cells (DCs) act as mobile sentinels of the immune system. By stimulating
T lymphocytes, DCs are pivotal for the initiation of both T and B cell-mediated
immune responses. Recently, ribonucleoprotein particles (vaults) were found to be
involved in the development and/or function of human DCs. To further investigate
the role of vaults in DCs, we examined the effects of the disruption of the major
vault protein (MVP) on the development and antigen presenting capacity of DCs,
using our MVP knockout mouse model. Mononuclear bone marrow cells were
isolated from wild-type and knockout mice and stimulated to differentiate to DCs.
Like the human DCs, the wild-type murine DCs strongly express MVP.
Nevertheless, the MVP deficient DCs develop normally and show similar expression
levels of several dendritic cell surface markers. No differences were observed in in
vitro studies on the antigen uptake and presenting capacities of the wild-type and
MVP knockout DCs. Moreover, immunization of the MVP deficient mice with
several T cell antigens led to similar responses as observed in the wild-type mice,
indicating that the in vivo DC migration and antigen presentation capacities are
intact. Also, no differences were observed in the induction the T cell-dependent
humoral responses and orally induced peripheral T cell tolerance. In conclusion,
vaults appear not to be required for primary DC functions.
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Introduction
Dendritic cells (DCs) are a heterogeneous population of antigen presenting cells
(APC) that function as sentinels of the immune system. By stimulating T
lymphocytes, DCs are pivotal for the initiation of both T and B cell-mediated
immune responses, for reviews see Cella et al. (1) and Banchereau et al. (2).
Moreover, by determining the nature of T cell responses, DCs regulate the Th1/ Th2
balance (3), and play an important role in peripheral T cell tolerance. Immature DCs
reside in non-lymphatic tissues and are characterized by a high capability for antigen
uptake and processing. Upon maturation, the cells lose their antigen uptake ability,
whereas MHC and costimulatory molecules are upregulated. The cells migrate to the
lymphoid organs where they find the right environment to activate antigen-specific T
cells (1). Recently two ATP-dependent transmembrane transporter molecules, P-gp
and MRP1, both known for their role in multidrug resistance (MDR), have been
identified as mediators in this migration process (4, 5). Whereas the role of P-gp in
this migration is as yet unclear, MRP1 regulates DC migration by transporting the
leukotriene C4 (LTC4). More recently, Schroeijers et al. confirmed the upregulation
of P-gp on developing DCs (6). They investigated DCs from different origins, such
as peripheral blood monocytes, CD34+ peripheral blood cells and cells from chronic
myeloid leukemia patients. Interestingly, another possible mediator of drug
resistance, the intracellular vault complex, was also found to be strongly upregulated
during human DC differentiation. Moreover, addition of MVP specific antibodies in
the culture medium resulted in decreased viability of the maturated dendritic cells. In
addition, these dendritic cells showed decreased expression levels of differentiation
and maturation markers, as well as costimulatory molecules (6). Their capacities to
induce T cell proliferation and IFN-γ release appeared to be impaired, suggesting
that besides P-gp and MRP1, also MVP and vaults may play a role in the survival
and functioning of dendritic cells.
Vaults are large ribonucleoprotein particles that are found in the cytoplasm of most
eukaryotic cells, as reviewed by Scheffer et al. (7). The complex consists of three
different proteins of 100, 193 and 240 kDa, known as MVP, VPARP and TEP1
respectively, and multiple copies of small, untranslated RNAs of 88-141 bases. The
typical shape of the vault complex, a barrel with an invaginated waist and two
protruding caps, as well as its constituents, appear to be conserved between species
(8-10).
Since the major vault protein (MVP), which makes up 70% of the total mass of the
complex, was identified as the lung resistance-related protein (LRP) (11), many
studies on the function of this intriguing particle have focussed on a role of vaults in
drug resistance. Indeed, in several independent studies an upregulation of MVP was
observed in drug resistance cell lines and tumors (12-15) and evidence was obtained
supporting the view that vaults act by transporting drugs away from their cellular
targets (16, 17). However, so far a direct involvement of vaults in MDR could not be
demonstrated in the MVP knockout mouse model that we recently generated, despite
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extensive studies on the sensitivity of the MVP deficient animals and cells to various
cytostatic drugs (18).
Using our MVP knockout mice, we set out to study the role of MVP and vaults on
the development and functioning of DCs in mice. It was hypothesized that putative
DC malfunctioning might lead to an impairment of both the T cell immune
responses as well as the T cell-dependent humoral immune responses. Hence,
besides in vitro studies on the DC development, we tested the in vivo immune
responsiveness of mice deficient for MVP. Since in humans a high expression of
MVP was observed in macrophages (12), we also examined migration and function
of macrophages derived from the MVP deficient mice.
Materials and Methods
Animals
MVP knockout mice were generated as described (18) and housed under
conventional conditions at the animal facility of the Erasmus MC. All animals used
in this study were of a mixed background of 129/Ola and C57BL/6 strains,
backcrossed for 1 to 4 generations to C57BL/6. Wild-type littermates were used as
controls in all experiments.
Bone marrow derived DC cultures
Bone marrow derived DCs were produced essentially as described (19). In short,
femurs and tibia were isolated from MVP+/+ and MVP-/- littermates. The bones were
cleaned and crushed in a sterile mortar in DC medium (RPMI medium with 10%
Fetal Calf Serum, 100 units/ml penicillin, 100 µg/ml streptomycin and 0.1 mM β-
mercapto-ethanol) in order to extract the cells. Subsequently, the cells were filtered
through a 100 µm cell strainer (Becton Dickinson, Franklin Lakes, NJ, USA) and
pelleted at 500 x g for 10 min. Mononuclear cells were separated from the bone
marrow cell suspension by density gradient centrifugation over lymphoprep 1.077
(Nycomed Pharma AS, Oslo, Norway) for 20 minutes at 833 x g. The deceleration
time of the centrifuge was set to 5 minutes. Cells were seeded at a density of 1.25 x
106 cells in 5 ml DC medium, complemented with 100 U/ml GM-CSF
(PeproTech/Tebu, Le Perray en Yvelines, France) in 25 cm2 bottles and cultured at
37°C in a humidified atmosphere containing 5% CO2. Three days after the isolation
of the mononuclear cells, an additional 5 ml of DC medium with GM-CSF was
added to the DC culture. Half of the DC medium was refreshed on days 6 and 8, and
on this last day, lipopolysaccharide (LPS) from E. coli (Sigma-Aldrich, St. Louis,
MO) was added to the medium at a final concentration of 1 µg/ml. For phenotypic
and functional analysis, the loosely adherent cells were harvested. Samples for
western blot analysis were taken on day 0, 3, 6, 8 and after overnight LPS
stimulation (day 9).
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Phenotypic and functional analysis of DC
DC phenotype was determined by FACS analysis using mAb: anti-CD11c-FITC,
anti-MHC class II-PE, biotinylated anti-MHC class II (all purchased from
PharMingen, Heidelberg, Germany); anti-CD40-PE, anti-CD80-PE, anti-CD86-PE,
anti-CD11b-PE (all obtained from Beckman Coulter, Mijdrecht, The Netherlands);
and the early myeloid marker-specific ER-MP58-FITC (20). Cells incubated with
biotinylated mAb were washed and stained with streptavidine-Cy-Chrome
(PharMingen). To be able to exclude dead cells from the analysis, 40 µg/ml 7-AAD
(Molecular Probes, Leiden, The Netherlands) was added prior to FACScan analysis
using CellQuest software (Becton Dickinson, Alphen a/d Rijn, The Netherlands).
To test the antigen uptake capacity of the DCs, 2 x 105 cells were incubated with 10
µl of a 10 mg/ml dextran-FITC solution (Sigma-Aldrich) in a total volume of 100 µl
DC medium. The cells were incubated at 37°C for 1 hour. The uptake was stopped
by the addition of ice-cold PBS and after washing, the cells were incubated with the
anti-MHC class II-PE antibody as a DC marker, for an additional 30 minutes on ice.
The background uptake of dextran-FITC was determined by incubating the cells at
4°C instead of 37°C.
Western analysis
Cell lysates were subjected to SDS-PAGE and the size fractionated proteins were
transferred to nitrocellulose. The membranes were blocked in TBST (50 mM Tris-Cl
pH 7.5, 100 mM NaCl, 0.05% (v/v) Tween 20) containing 5% (w/v) nonfat dried
milk (Bio-Rad, Laboratories, Hercules, CA). MVP was detected using a rabbit
polyclonal antiserum raised against human MVP (21) and an anti-rabbit Ig
conjugated to horseradish peroxidase (Jackson ImmunoResearch Laboratories,
Westgrove, PA) as second antibody. Immune-complexes were detected using the
BM chemiluminescence (Roche Molecular Biochemicals, Mannheim, Germany) and
visualized on Hyperfilm ECL (Amersham-Pharmacia, Uppsala, Sweden).
Quantifications were performed using ImageQuaNT version 3.3 (Molecular
Dynamics, Sunnyvale, CA).
Allogeneic mixed lymphocyte reaction
To determine the capacity of the DCs to stimulate T cell proliferation, splenocytes
from BalbC mice were stimulated with dendritic cells derived from wild-type and
MVP knockout mice with a C57BL/6-129 OLA background (18). Spleen cells were
isolated by squeezing the spleens through a wetted 100 µm cell strainer (Becton
Dickinson) and spinning the cells for 5 minutes at 558 x g. Splenocytes (104 per
well) were mixed with DCs in ratios ranging from 5:1 to 1280:1 (spleen cells: DCs),
and seeded in round bottom 96-wells plates in 200 µl DC medium. After 3-5 days of
incubation at 37°C, 0.1 µCi/well [3H]-thymidine (Amersham, Buckinghamshire,
UK) was added and the cells were incubated overnight. Cells were transferred to a
glass fiber filter using a filtermate 196 cell harvester (Packard Instrument BV,
Groningen, The Netherlands) and the radioactivity retained on the filters was
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determined by a topcount microplate scintillation counter (Packard Bioscience). All
incubations were performed in quadruplicate.
Macrophage phagocytosis and migration tests
To isolate macrophages, two wild-type and two MVP knockout animals were
injected i.p. with 1.5 ml paraffin oil. After 48 hours, the animals were sacrificed and
abdominal cavities flushed with 6 ml of IMDM (Bio Whittaker, Verviers, Belgium),
containing 10% FCS and 50 IE/ml heparin, to harvest the cells. The numbers of
cells, reflecting in vivo migration, were counted and the cells were resuspended in
200 µl IMDM with 10% heat inactivated mouse serum. For the in vitro migration
test, 0.5 µl of this cell suspension was transferred to a well of a microtiter plate and
the cells were allowed to adhere for 30 minutes. Then, 3 times 25 µl of medium was
added slowly to the wells, taking care that the cells remained attached to the plastic.
Using an ocular raster, squares containing macrophages were identified and
recorded. The migration capacity of the cells was subsequently determined by
counting the numbers of cells that had migrated out of these original squares after 24
hours.
To test the phagocytic capacity of the macrophages, 50 µl of the macrophage cell
suspension was added to 500 µl PBS containing 1% BSA and 1 mg/ml dextran-
FITC. After incubation at 37°C (or on ice as a negative control) for 1 hour, the cells
were washed with and resuspended in 500 µl ice-cold PBS containing 1% BSA. The
amounts of intracellular dextran-FITC taken up by the cells were determined by
FACScan.
Sensitization and skin testing to different antigens
For sensitization with keyhole limpet hemocyanin (KLH, Perimmune, Seattle, WA),
5 wild-type and 5 MVP deficient mice were injected with 100 µg KLH
subcutaneously in the right hind foot pads. After 10 days, the animals were
challenged with 5 and 10 µg KLH subcutaneously in the ears. The thickness of the
ears was measured before, and 4, 24, 48 and 72 hours later. Following essentially the
same protocol, 3 days later, all mice were again sensitized, i.e. by subcutaneous
injection of 50 µg ovalbumin (OVA, Sigma-Aldrich, St. Louis, MO) in the left hind
foot pads, and skin tested 7 days later by injecting 10 µg OVA in the right ear. A
third sensitization and testing round was finally made with the widely used contact-
allergen dinitro-chlorobenzene (DNCB). To this end, the animals were sensitized by
application of 20 µl of a 1% DNCB solution in EtOH, e.c. on the abdomen. After 4
days, they were challenged with 2 x 10 µl of 0.3% DNCB in EtOH e.c. on the left
ear. Swelling of the ears was again measured at 4 to 72 hours after the challenge.
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Oral tolerance test
6 wild-type animals and 6 MVP knockout animals were fed three times with 10 mg
ovalbumin on day 1, 3 and 8. Control animals obtained the same volume (200 µl) of
saline. Immunization was performed on day 13, with 50 µg ovalbumin,
subcutaneously injected in the foot pad. After 7 days, the animals were challenged
i.c. in the ear with 10 µg ovalbumin. Ear swelling was measured at 4, 24, 48 and 72
hours after the challenge.
Antibody shift
Sera of other groups of 6 wild-type and 6 MVP knockout mice that were KLH
immunized (day 0) and challenged (day 10) as outlined above, were tested for the
production of anti-KLH antibodies by ELISA. Flatbottom microtiter plates were
coated overnight with 1 µg KLH per well. Each of the mouse sera was diluted in a
three-step dilution series from 1:10 till 1:21870 and the anti-KLH antibodies in the
serum were detected with goat anti-mouse IgG, IgG1 or IgG2a. As a second
antibody, rabbit anti-goat-HRP was used. Between the successive steps, the plates
were washed 2 x 15 sec in tap water containing 0.05% Tween 20. Bound antibody
was detected by a color reaction using O-phenylenediamine (OPD). After 30 min the
reaction was stopped by the addition of 50 µl of 2.5 M H2SO4 and the optical density
(OD) at 492 nm was determined.
Results
Phenotypic analysis of MVP deficient DCs
Mononuclear cells isolated from total bone marrows from wild-type and MVP
knockout mice were cultured for 9 days, in the presence of GM-CSF to induce DC
differentiation. On day 8, LPS was added to the culture medium as a maturating
agent. In order to investigate whether MVP deficiency might interfere with DC
development, mature DCs derived from wild-type and MVP knockout bone marrow
were harvested after overnight stimulation with LPS. By FACScan analysis, the
expression of several DC surface markers and costimulatory molecules on the MVP
deficient cells was determined and compared to the levels on wild-type cells.
Overlays of knockout and wild-type FACS histograms are shown in Figure 1.
The cell surface levels of the DC marker CD11c, the early myeloid marker ER-
MP58 (20), the myeloid marker CD11b, MHC class II molecules and t h e
costimulatory molecules CD40 and CD80 were similar in the MVP knockout and
wild-type DCs. One of the costimulatory markers, CD86, was expressed at a slightly
lower level on the MVP knockout DCs. However, the cells were still clearly positive
for this marker and the other costimulatory molecules were expressed normally.
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Figure 1. Phenotypic analysis of DCs derived from wild-type and MVP knockout mouse
bone marrow. Expression levels of 7 different cell surface markers on wild-type and MVP
deficient cells were determined by FACS analysis. Grey plots present marker expression in
DCs derived from wild-type bone marrow, black overlays present expression in MVP
deficient DCs. The fluorescence is shown on the x-axis, cell counts are shown on the y-axis.
The fluorescence levels were clearly distinguishable from the routinely included negative
controls (not shown).
Expression of MVP during murine DC development
Samples of wild-type total bone marrow, immature DCs and mature DCs were taken
and subjected to western blot analysis, in order to determine MVP expression levels.
As shown in figure 2, the expression of MVP in total bone marrow is relatively low.
During differentiation (day 3 - day 8) in cultures with GM-CSF, MVP became more
highly expressed (3-fold compared to unstimulated mononuclear bone marrow
cells). Subsequently, like in human DCs (6), LPS stimulation (day 9), seemed to
enhance the expression of MVP even further (6-fold compared to the unstimulated
mononuclear bone marrow cells). Of note, at day 3 of the differentiation culture,
when numbers of differentiated DCs are still low (19), MVP was already highly
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expressed on the cells, suggesting that MVP expression might be related to processes
in early myeloid development.
Figure 2. MVP expression in dendritic cells. Total bone marrow was isolated from wild-
type mice. The mononuclear cells were isolated and cultured in the presence of GM-CSF.
Samples were taken at day 3, 6, 8 and 9. Protein lysates corresponding to equal numbers of
cells were subjected to SDS-PAGE and analyzed for MVP expression by Western blotting.
Note that on day 8, the dendritic cells were overnight stimulated with LPS.
DC antigen handling and presentation
DC function was tested by measuring the in vitro dextran uptake capacity. The
internalized dextran-FITC was similar in MVP+/+ and MVP-/- DCs (Figure 3A). Cells
incubated with dextran-FITC at 4°C (negative controls) showed only low levels of
dextran-FITC uptake (results not shown).
Subsequently, the antigen presenting capacity was tested by means of mixed
lymphocyte reaction (MLR) assays. For this, the DCs from wild-type and MVP
knockout bone marrow were mixed with lymphocytes isolated from allogeneic
spleens. The induced proliferation of the lymphocytes was measured after 4 days. As
is clear from Figure 3B, the MVP knockout DCs are perfectly capable of inducing T
cell proliferation. No differences were observed between the proliferation of
lymphocytes incubated with wild-type and MVP knockout DCs.
0 3 6 8 9  days
MVP
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Figure 3. Functional analysis of DCs derived from wild-type and MVP knockout mouse
bone marrow. A) Histogram plots of the uptake of dextran-FITC at 37°C by wild-type (grey
plot) and MVP deficient (black) DCs. B) Mixed lymphocyte reaction (MLR). Lymphocytes
were mixed with DCs from wild-type (black dots) and MVP deficient DCs (white squares).
On the x-axis, the ratios of lymphocytes: DCs are indicated on a logarithmic scale. The
proliferation of lymphocytes is measured by the incorporation of [3H]-thymidine and
expressed as counts per minute (cpm) on the y-axis. When the number of DCs increases, the
lymphocytes show a stronger proliferation.
Macrophage migration and function
To explore macrophage migration and phagocytosis capacity from MVP deficient
mice, two wild-type and two knockout animals were injected with paraffin oil. After
two days, the macrophages were isolated from the peritoneal cavity. The numbers of
cells that had migrated from the blood into the peritoneal cavity reflect the in vivo
migration capacity of the macrophages. As is shown in table 1, the numbers of
macrophages were comparable in wild-type and MVP knockout mice. Next, in vitro
migration assays were performed. Percentages of migrated macrophages were
counted 24 hours after seeding and appear comparable in wild-type and MVP
deficient cells (Table 1). The phagocytosis capacity was tested by incubating the
isolated macrophages with a dextran-FITC solution and quantification of the
phagocytosed material by FACS analysis. Percentages of cells containing dextran
are shown in table 1. The MVP deficient macrophages migrate normally and are as
capable of taking up FITC-labeled dextran as the wild-type macrophages.
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Table 1. Migration and phagocytosis of macrophages from wild-type and MVP
knockout mice.
cell number viability migration phagocytosis
Wild-type
(n = 2)
1.3-2.5 x 107 78-87% 55-64% 17.6-33.5%
Knockout
(n = 2)
0.8-2.8 x 107 82-83% 64-70% 15.1-41.4%
Shown are numbers of macrophages isolated from the peritoneal cavity (first column) and the
viability of these cells (column 2). Percentages of macrophages that migrated during the in
vitro migration experiment are shown in column 3. The last column shows the percentages of
macrophages that have taken up dextran-FITC, after an incubation of 1 hour at 37°C, as
measured by FACScan analysis.
In vivo immune responses
Although the MVP deficient DCs have essentially similar phenotypic characteristics
as the wild-type DCs and appear functional in in vitro tests, their in vivo migration
from immunization sites to the draining lymph nodes and their subsequent in vivo
antigen presenting capacities might still be affected. In turn, this might lead to
impaired T cell responsiveness. To test this possibility, 5 wild-type and 5 knockout
animals were immunized with three different antigenic materials well-established for
their capacity to provoke T cell-mediated immune responses. After challenging,
immune responses were evaluated by measuring the delayed type hypersensitivity
reactions in the challenged ears.
While these reactions for the protein antigens KLH and ovalbumin are supposed to
reflect T-helper cell type 1 (Th1) responses, the contact allergen DNCB may induce
both Th1 and T-helper cell 2 (Th2) responses. The results of these experiments, as
presented in Figure 4A, show that the responses to all antigens examined were
similar in wild-type and MVP knockout mice. As expected, the PBS injected control
animals showed low responses. These data suggest that the disruption of MVP has
no significant effects on the development of T cell-mediated effector functions as
revealed by skin hypersensitivity reactions.
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Figure 4. Immune responsiveness of wild-type and MVP deficient mice immunized with
several allergens. A) In all experiments, 5 wild-type and 5 knockout mice were immunized
subcutaneously and challenged after 10 (KLH), 7 (OVA) or 4 (DNCB) days, in the skin of the
ear or limb. Control wild-type animals were injected with equal volumes of saline. The
swelling at the site of the challenge (thickness of the ear/limb minus original thickness) by is
a measure for the immune responsiveness and is shown on the y-axis. Black bars present
response of wild-type animals, grey bars present the response of MVP deficient animals and
white bars present saline injected control animals. Error bars indicate 2 x SD (n = 5). B) Oral
tolerance test to ovalbumin. 6 wild-type and 6 MVP knockout animals obtained 3 times 10
mg ovalbumin intragastrally. Control animals obtained a physiological salt solution, in a
similar volume. The animals were immunized in one of the limbs, and challenged in the ear.
The swelling of the ear is a measure for the immune responsiveness. Black bars present
response of wild-type animals, grey bars present the response of MVP deficient animals and
white bars present the response of the (wild-type) positive control animals. Error bars indicate
2 x SD (n = 5).
Induction of oral tolerance
The expression of MVP was found to be high in tissues of the gastro-intestinal tract
(12). This might point to a role of MVP and vaults in a protective response to food
allergens. To examine this option, we fed both wild-type and MVP knockout mice
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three times 10 mg of ovalbumin. Such repeated feeding is known to induce an
incapacity of the animals to subsequently develop T cell-mediated immune
responses, reflecting immunological tolerance. When immunization with ovalbumin
was attempted, only the positive control saline fed animals showed proper immune
responses to ovalbumin. MVP deficient animals displayed an equally decreased
responsiveness to ovalbumin as the wild-type animals (Figure 4B), proving that
induction of oral tolerance in the MVP knockout mice is unimpaired. Apparently,
these mice do not exhibit major defects in food handling.
T cell-mediated humoral responses
Besides the initiation of primary immune responses, DCs also play a role in the
modulation of immune responses by regulation of the Th1/Th2 balance (reviewed by
Shortman et al. (3)), as reflected by the preferential production of distinct antibody
isotypes. Possibly, the disruption of MVP might change the preference for either a
Th1 or a Th2 response and as a consequence the production of antibody isotypes
associated with these responses, e.g. IgG1 versus IgG2a. We therefore investigated
the subclasses of the antibodies produced upon immunization with KLH. Sera of
KLH immunized animals were tested by ELISA. The results are shown in Figure 5.
The titers of total IgG, IgG1 and IgG2a are similar in wild-type and knockout
animals, suggesting that besides proper T cell-mediated immunity, also the T cell-
dependent humoral antibody production to KLH is unaffected.
Discussion
Recently, Schroeijers et al. reported that MVP, the major component of the vault
complex, is upregulated during the development of human DCs (6). Moreover, the
presence of MVP specific antibodies, presumably interfering with the function of
MVP or vaults, resulted in reduced expression levels of DC markers and
costimulatory molecules and a decreased capacity to induce T cell proliferative and
IFN-γ releasing responses. Previously, we reported the generation of a MVP
knockout mouse model (18), in which vault particles are absent (Mossink et al.,
unpublished data). Using this model, we investigated the role of MVP and/or vaults
in the maturation and function of DCs. Although MVP is highly expressed in mature
wild-type DCs, the loss of this protein did not alter the in vitro development and
function of DCs derived from mononuclear bone marrow cells. In addition, in vivo
immunization assays showed that neither the T cell-mediated immune response nor
the T cell dependent humoral response are affected by the disruption of MVP,
indicating intact antigen presenting and migration capacities of the DCs.
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Figure 5. T cell-dependent humoral immune responsiveness. Anti-KLH antibodies in the
serum of KLH immunized mice. A range of serum dilutions was analyzed for total IgG, IgG1
and IgG2a by ELISA as described in Materials and Methods. The results are expressed as
mean ± SD of 6 wild-type animals (black dots), 6 MVP deficient animals (white squares) or 3
control, saline injected animals (black triangles).
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Apparently, the clues for an involvement of MVP and vaults in DC development and
function, as reported earlier for human DCs (6), were not further substantiated using
the MVP knockout mouse model. This could point to a fundamental difference
between DCs from human and mouse. However, it should be considered that the
decreased viability, lower expression of DC markers and reduced antigen-
stimulatory capacity reported were observed with DCs cultured in the presence of
polyclonal, or pooled monoclonal, anti-MVP antibodies. The lack of effects with
individual monoclonal antibodies was noted to argue against interference with
functionally relevant epitopes. Rather, the blockade of DC functions could result
from events secondary to the binding of anti-MVP, e.g. from aggregation of vault
particles (6). The present results, showing that the mere absence of vault particles
does not significantly affect phenotypic and functional DC markers, support the
latter option. Nevertheless, a role of vaults in DC antigen presenting functions can
not be fully excluded since the loss of MVP and vaults might still result in subtle
effects beyond the scope of the presently used experimental conditions and assays.
Possibly, gene products playing roles in critical cellular functions show redundancy,
with other factors compensating for their eventual loss. The latter option is, however,
difficult to reconcile with the unique structure of the vault complex, and the lack of
MVP homologues in the murine genome (10).
In summary, the functional impact of highly expressed MVP in mammalian DCs
remains unclear. Since the high expression levels in DCs have, thus far, primarily
been studied in in vitro cultured cells, further analyses of conditional upregulation of
MVP levels in DCs in vivo in human and mouse lymphoid tissues are warranted. In
early immuno-histopathological analyses of human lymphoid tissues we noted high
levels of MVP in macrophage-like cells, but not in DCs (12). Given the present
results showing that lack of vault particles also does not interfere with primary
macrophage functions, notably migration and phagocytosis, we currently focus on
their potential role in controlling cell division processes. Such a role(s) might fit
with recent data on the association of MVP with the tumor-suppressor factor PTEN
(22), as well as with their frequent overexpression in cytostatic drug resistant tumor
cells. The present data reveal that vaults are not required for primary DC functions.
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Vaults and DNA damage repair: a role for VPARP?
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Abstract
The only vault component that is known to exhibit enzymatic activity is VPARP,
which is able to poly(ADP-ribosyl)ate itself and the major vault protein and possibly
other proteins. Other members of the PARP protein family such as PARP-1 and
PARP-2 are involved in DNA damage repair, more specifically in the base excision
repair pathway, whereas tankyrase-1 and tankyrase-2 appear to play a role in the
telomere length regulation.
To investigate whether VPARP also plays a role in the DNA damage repair
pathways, we treated MVP knockout embryonic stem cells, that were found to
contain markedly reduced amounts of VPARP and TEP1, with DNA damage
inducing conditions, like UV light, γ-irradiation and mitomycin C. The survival of
the MVP knockout cells in all conditions was identical to the survival of wild-type
cells treated with the same conditions, implying that intact vault particle and most
likely VPARP are not involved in DNA damage repair. The poly(ADP-ribosyl)ation
activity of VPARP might be essential in other cellular processes.
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Introduction
Vaults are ribonucleoprotein particles of around 13 MDa, consisting of the three
proteins MVP (100 kDa), VPARP (193 kDa) and TEP1 (240 kDa), and multiple
copies of small untranslated RNA molecules of 88-141 bases (1). The function of
vaults is unknown, but it is often suggested that these particles are involved in drug
resistance (reviewed in Chapter 1).
MVP, the Major Vault Protein makes up over 70% of the total complex. TEP1 and
VPARP are named minor vault proteins (MiVP) and both also occur in non-vault
associated forms in the cell. TEP1 is a shared subunit with the telomerase complex
where it binds telomerase RNA (2). VPARP is located in the nucleus and during
mitosis, it co-localizes with β-tubuli into the mitotic spindle (3). It is not clear
whether these non vault-associated fractions of TEP1 and VPARP fulfil separate
functions, unrelated to the function of vaults.
VPARP, which was cloned by Kickhoefer et al. (3), contains a poly(ADP-ribose)
polymerase (PARP) domain. This protein domain can catalyze the covalent addition
of ADP-ribose units to acceptor proteins. In vitro experiments indicate that VPARP
is able to ribosylate itself as well as MVP. Other substrates might exist, but have not
been identified yet. The relevance of the poly(ADP-ribose) polymerase activity for
vault function is unknown yet, but so far VPARP is the only vault component that
exhibits an enzymatic activity.
The first protein reported to display PARP activity is PARP-1. This nuclear enzyme
can recognize and bind to nicked DNA and appears to be involved in the base
excision repair (BER) pathway. In fact, poly(ADP-ribosyl)ation, is an immediate
response to DNA damage (for a review see Oliver et al., Ref. 4). So far, seven
additional human proteins with PARP activity have been described (Figure 1).
PARP-2, which shows the highest similarity to PARP-1, is also involved in base
excision repair pathway (5). Two other members of the PARP family, tankyrase-1
(PARP-5) and tankyrase-2, are associated with the end of chromosomes, the
telomeres. They might act as telomere-length regulators, since both proteins bind to
the telomeric protein TRF1 and the ADP-ribosylation of TRF1 reduces its ability to
bind telomeric DNA (6, 7). In contrast, PARP-3 can bind to DNA but is present in
the centrosome (8). PARP-6 and PARP-7 have not yet been well characterized (9,
10) and no information is available on their DNA binding capacity and subcellular
localization (8). The similarity between the PARP domains with the catalytic domain
of PARP-1 ranges from 29% (VPARP) to 60% (PARP-2).
Although the PARP family members show no or little homology outside the PARP
domains (Figure 1), it is possible that a general role of PARP family members is the
maintenance of genomic stability.
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The nuclear localization of the non vault-associated VPARP fraction fits with this
idea (3). Moreover, VPARP contains a BCRT domain, a widespread motif in
proteins involved DNA damage repair, which is also present in PARP-1, where it
mediates the interaction with the base excision repair complex protein XRCC1 (11).
Interestingly, the correlation between vaults and multidrug resistance might be
explained by assuming an involvement of VPARP in DNA damage repair pathways.
Many drugs used in chemotherapy protocols directly or indirectly target the DNA of
tumor cells; for example by inhibition of topoisomerase-II (etoposide), by the
induction of interstrand crosslinks (nitrogen mustards and platinum adducts), or by
DNA intercalation (anthracyclins). VPARP might function in the various repair
processes and by this action decrease the sensitivity of the cells against the cytotoxic
agents.
In the MVP knockout mouse model that we generated (12), the levels of the minor
vault proteins TEP1 and VPARP are also markedly decreased as a consequence of
the absence of MVP (See Chapter 4). Hence, the lack of MVP might directly affect
the hypothetical DNA damage repair activity performed by VPARP. In this study,
we investigated whether MVP -/- cells show an increased sensitivity to DNA
damaging agents. We tested the sensitivity of our MVP-/- embryonic stem cells to
UV irradiation, which will cause base damage and leads to base excision repair and
nucleotide excision repair (NER) pathways (13). Several independent studies
showed that PARP-1 deficient mice and cells are hypersensitive to ionizing
irradiation (e.g. 14-16). We therefore also exposed the MVP-/- cells to γ-rays. Among
other types of DNA damage, γ-rays induce double strand breaks (DBS) that can be
repaired by homologous recombination and/or chromosome end-joining (13).
Finally, interstrand cross-links were induced by exposure to the alkylating agent
mitomycin C (17). The repair of this type of DNA damage involves DBS and NER
pathways.
Materials and Methods
Materials
Mitomycin C was purchased from Kyowa Hakko Kogyo, (Tokyo, Japan).
ES cells
Embryonic stem cells with a disruption on both MVP alleles were generated and
cultured as described (12).
Cell survival curves
The sensitivity of wild-type and MVP-/- ES cells to increasing doses of mitomycin C,
UV or ionizing irradiation was determined by measuring their colony forming ability
(18). The ES cells were trypsinized and counted. Various cell dilutions (ranging
from 500 till 12000 cells per dish) were seeded on gelatinized 60 mm dishes. After
24 hours, the cells were incubated with mitomycin C for 1 hour after which the cells
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were washed and the fresh medium added. For UV irradiation (λ=254 nm), the
medium was replaced with PBS, prior to exposure. Ionizing irradiation sensitivity
was determined by comparing the colony-forming ability of the ES cells after
irradiation with a 137Cs source. The cells were incubated at 37°C, 5% CO2 in a
humidified atmosphere for 7-10 days and colonies were fixed (and stained) with
50% methanol, 7% acetic acid, 43% water and 0.1% Commassie Blue. All
measurements were performed in triplicate. The number of colonies present in the
dishes seeded with untreated cells was set to 100%. The relative cloning efficiency
of treated cells was corrected for the number of cells seeded.
Results
Analogous to PARP-1 and PARP-2, VPARP may be involved in the base excision
repair (BER) pathway. It was hypothesized that the MVP knockout cells, having
decreased levels of VPARP, exhibit an impaired base excision repair pathway,
resulting in an increased sensitivity to DNA damaging agents such as UV light.
MVP+/+ and MVP-/- ES cells were treated with increasing intensities of UV light,
ranging from 0 - 8 Joule/m2. Subsequently, the survival of the cells was determined
in a colony forming assay. The number of colonies was corrected for the number of
seeded cells in each plate and compared with untreated cells. The survival curves are
shown in Figure 2A. Cell survival dropped to 20% at a 2 J/m2 dose until virtually
none of the cells survived at 8 J/m2. However, no significant differences were
observed between MVP wild-type and knockout cells. To test whether the decreased
levels of VPARP affect other DNA damage repair pathways besides BER, such as
homologous recombination, we exposed the cells to ionizing irradiation and an
alkylating agent, mitomycin C. The survival curves are shown in Figure 2B and 2C.
The survival of the cells decreases upon exposure to higher doses. However, also
under these conditions the wild-type and MVP knockout cells displayed an equal
sensitivity.
Discussion
The hypothesis that vaults and/or VPARP are involved in DNA damage repair was
tested by exposing wild-type and MVP-/- cells to several DNA damage inducing
conditions and determining the cell survival in colony forming assays. Three
different treatments were performed to induce different DNA lesions, such as base
damage, double strand breaks, and interstrand cross-links.
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Figure 2. Effects of UV light, ionizing radiation and mitomycin C exposure on wild-type
and MVP knockout cells. A) Clonogenic survival of MVP+/+ and MVP-/- ES cells after
treatment with increasing doses of UV light. After the exposure, the cells were allowed to
form individual colonies. The percentage of surviving cells, as measured by the colony
forming capacity, is plotted as a function of the UV dose. Black diamonds represent wild-
type cells, white squares represent MVP deficient cells. All measurements were performed in
triplicate, shown are averages ± S.D. Consistent results were obtained in several independent
experiments. B) Clonogenic survival of MVP+/+ and MVP-/- ES cells after treatment with
increasing doses of γ-rays. C) Clonogenic survival of MVP+/+ and MVP-/- ES cells after
treatment with increasing concentrations of the cross-linking agent mitomycin C.
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No differences were observed in the sensitivity of the two cell lines and we conclude
that the absence of MVP, and consequently the absence of vaults, does not interfere
with the efficiency of the various DNA damage repair mechanisms. Likewise, the
decreased amounts of the remaining vault proteins TEP1 and in particular VPARP in
MVP knockout cells do not lead to an increased sensitivity to DNA damaging
agents. Actually, these results are consistent with our previous observations, that
disruption of MVP did not increase the sensitivity of the cell to various cytostatic
agents, of which several act by inducing DNA damage (12).
The common denominator of the PARP family of proteins, the poly(ADP-ribose)
polymerase activity, might indeed identify proteins functioning at different levels in
the maintenance of the genomic stability. Alternatively, poly(ADP-ribosyl)ation may
be essential for the regulation of various unrelated cellular processes. Our results
favor the latter alternative. Identification of other VPARP substrates might therefore
be an important step in understanding the function of VPARP and vaults.
However, an involvement of VPARP in DNA repair mechanisms cannot be
completely excluded. Although VPARP is strongly reduced in the MVP deficient
cells, the remaining fraction of the protein might be sufficient for its action. Perhaps
even, the disruption of MVP only affects the vault associated levels of VPARP,
while the nuclear fraction remains stable. Alternatively, other proteins exhibiting a
comparable mechanism such as PARP-1 and PARP-2 could take over the action of
VPARP.
To exclude the involvement of VPARP in DNA damage repair, one should
investigate the effects of the total absence of VPARP, for example in a VPARP
knockout model. A VPARP knockout model in which PARP-1 and PARP-2 are
already disrupted might be even more conclusive. Meanwhile, the localization of the
remaining VPARP in our MVP knockout mouse model is an interesting subject of
investigation and could point out the site where VPARP activity is essential.
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Introduction
In 1986, Kedersha and Rome were the first to describe a novel and intriguing
ribonucleoprotein particle, that was named the vault complex (1). This large 13 MDa
particle appeared to have a typical barrel-shaped morphology, which has been
conserved in evolution (2). The mammalian vault complex is composed of multiple
copies of the 100 kDa major vault protein (MVP), two minor vault proteins of 193
kDa (VPARP) and 240 kDa (TEP1) as well as small untranslated RNA molecules of
88-141 bases. In the past years, we have gained new insights into the structure of
vaults (3-5) and the individual vault components have been identified (6-8).
However, the cellular function(s) of the vault complex remain an enigma. Several
vault-mediated cellular processes have been proposed in the literature, but for most
of them there is little evidence. Most commonly, based on their hollow, barrel-like
structure, subcellular localization and dynamics, vaults are regarded as intracellular
transport modules (9-13). However, the cargo that is supposedly transported still has
to be identified.
In 1995, the Lung Resistance-related Protein (LRP) was identified as the human
major vault protein (14), which led to renewed interest in vaults as possible
mediators of multidrug resistance (MDR). Many clinical studies have suggested the
existence of a correlation between MVP expression and MDR (reviewed by Scheffer
et al., 15 and in Chapter 1). However, convincing proof for a direct involvement of
vaults in drug resistance and/or intracellular drug transport and sequestration is still
lacking.
The studies presented in this thesis, were performed to address the following
questions:
1. Are vaults mediators of drug resistance and if so, what is the molecular basis?
2. What is the physiological function of vaults?
Project strategy
To approach the questions raised above, we have generated a mouse model in which
vaults are (functionally) absent. Knockout mouse models have been used to
investigate the significance and function of the MDR proteins P-glycoprotein (P-gp)
and the multidrug resistance associated protein (MRP1) (16-18). One has to consider
though, that in contrast to vaults, P-gp and MRP1 were already identified as drug
efflux pumps and the knockout models were merely used to substantiate these
findings and obtain insight in the physiological function of these proteins (see for
recent review Ref. 19).
Another issue was how to generate a functional vault knockout, with the vault
particle being a multi-protein complex. MVP however, is thought to be the main
structural component of the vault complex, accounting for 70% of the molecular
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mass. Expression of only MVP in insect cells that are lacking vaults, is sufficient for
the formation of vault-like particles (20). Therefore, absence of MVP will probably
lead to disruption of the whole vault particle and hence it was decided to generate a
MVP knockout mouse as a model for the role of vaults in drug resistance.
The MVP knockout mouse
The high degree of evolutionary conservation of MVP has been illustrated in
Chapter 2. The primary sequences of MVPs from different species, including higher
and lower eukaryotes, were found to be highly identical. Moreover, the genomic
organization of the murine MVP gene closely resembled the intron-exon structure of
the human MVP gene (21, 22). Furthermore, the promoters of the genes are similar
too, suggesting a comparable mechanism of regulating MVP gene expression.
As was shown in Chapter 3, the MVP knockout mice are viable, fertile and show no
gross abnormalities up to 16 months of age. Thus, at least in the protective
environment of our animal facility, the loss of MVP does not interfere with the
development, viability and reproduction. However, part of the function of vaults
may still be performed by the remaining vault components. Therefore we
investigated the effects of MVP disruption on vault particles and on the remaining
vault components. In Chapters 3 and 4, it was shown that the disruption of MVP
results in the loss of the whole vault particle, which could no longer be detected in
MVP-/- tissues. The absence of MVP also appeared to have dramatic effects on the
steady-state levels of the other vault components. This indicates that, most likely,
also the non-vault associated fractions of TEP1, VPARP and vRNA are functionally
disrupted in the MVP knockout cells and tissues. These results stress the uniqueness
and the relevance of the MVP knockout mouse model in the search for the function
of vaults; TEP1 and VPARP knockout mice have also been generated (8, 23), but
both knockout mice still appear to contain distinguishable vault particles, composed
of MVP and/or other vault components.
The MVP knockout mouse and drug resistance
Although the MVP knockout mice are normal and healthy and have no apparent
phenotype, vault function may be required under certain challenging conditions.
Such was the case in the P-gp and MRP1 knockout mouse models that also lacked a
phenotype until they were properly challenged by exposure to certain cytotoxic
drugs.
In Chapter 3, we examined whether disruption of MVP increased the sensitivity of
ES and immature bone marrow cells to various cytostatic drugs, by performing both
cell survival assays and cell proliferation assays. No differences were observed in
the sensitivity of wild-type and MVP knockout cells, despite the large test panel of
drugs, which provoke different kinds of toxicity. Since there is a possibility that
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vaults function in the systemic protection rather than in cellular protection, the
effects of in vivo administration of a cytostatic drug, doxorubicin, were investigated.
The in vivo toxicity of doxorubicin was equal in the MVP knockout mice compared
to wild-type mice.
Taken together, we were not able to demonstrate a direct relation between vaults and
drug resistance. We have to keep in mind though that our studies only included
short-term exposure to cytotoxic drugs, whereas vaults could be specifically
involved in the protection to long-term exposure to low concentrations of drugs.
The physiological function of vaults
In addition to a possible role in drug resistance, the literature suggests an
involvement of vaults in various other cellular processes. A number of putative vault
functions could easily be tested, exploiting our MVP knockout mouse model. Firstly,
vaults were reported to be essential for the development and/or functioning of
dendritic cells (24). However, in the MVP knockout mice, the development and
functioning of dendritic cells, examined in Chapter 5, appeared normal. Moreover,
the animals showed normal responses to several allergens, indicating the proper
functioning and migration of antigen presenting dendritic cells in these mice. A
second possibility, prompted by the enzymatic activity of VPARP (7), was a relation
between vaults and DNA damage repair mechanisms. MVP knockout cells that were
shown to contain clearly reduced amounts of VPARP (Chapter 4) were exposed to
several DNA damage inducing conditions. The cell survival curves in Chapter 6
demonstrate that the disruption of MVP and as a consequence vault particles, did not
lead to an increased sensitivity to DNA damage inducers.
Vaults: Organelles without a function?
The normal development and viability of MVP deficient mice, and in particular the
lack of a phenotype in drug sensitivity, immune response and DNA damage assays,
do not completely rule out a role for vaults in any of these processes. It is possible
that in the absence of MVP, other proteins take over its function. In Dictyostelium
discoideum for example, three MVP homologues were identified (25, 26). However,
the murine genome does not contain MVP related genes, as was shown in Chapter 2
and if an unknown factor is capable of functionally replacing MVP, it does not seem
to form structures with the physico-chemical properties of genuine vault particles
(Chapter 3 and Chapter 4). Alternatively, other multidrug resistance mechanisms,
with overlapping substrate profiles, might compensate for the loss of MVP and
vaults. However, the activities of the well-described MDR related proteins, P-gp,
MRP1 and BCRP were not upregulated upon MVP disruption (Chapter 3). Finally,
the remaining levels of the minor vault proteins and vRNA may still exert some
basic vault function and hence the deletion of MVP  might cause only subtle
Chapter 7
117
differences. However, given the uniqueness of the vault structure, the dramatic
effects of the absence of MVP on the levels of the minor vault proteins and the fact
that the TEP1 knockout model also lacks a phenotype, it seems far more likely that
we simply have not yet discovered the specific challenging conditions that require
vault function.
Future directions
The generation of additional vault knockout models
So far, both the MVP knockout and the TEP1 knockout mice lack a phenotype. In
addition, although the characterization of these mice has not yet been reported, the
VPARP  knockout mice are also viable. A model in which all known vault
components, including the vRNA gene, are disrupted will most likely also not exhibit
a clear phenotype. Yet, such a model could be helpful in the search for the function
of vaults. Intercrossing the various knockout mice that are available now is therefore
a logical strategy to resolve the discussion about possible active remnants of the
vault complex.
Identification of associated proteins and/or cargo’s
An approach to gain insight in the cellular function of the vault complex is to search
for additional vault- or vault-interacting proteins and/or the possible cargo of vaults.
The in vivo active vault particle might consist of more components than the already
identified 100, 193 and 240 kDa proteins and the RNA molecules. The first reports
on vaults mention the presence of a 54 kDa protein (1). Only recently, this protein
was identified as the La auto-antigen that interacts with the vRNA (27). There might
be even more additional proteins that bind loosely to the complex, or only associate
with vaults under specific conditions, which are lost during vault purification.
Recently, it was demonstrated by yeast two-hybrid analysis and co-
immunoprecipitation experiments that MVP/vaults interact with the tumor
suppressor PTEN in Hela cells (28). The authors suggest that vaults mediate the
cellular localization of PTEN, but the biological significance of this interaction is
still unclear. Possibly, the activity of PTEN is influenced by its association with
vaults. Additional binding partners of the vault complex, identified by similar
approaches, could help to point out the physiological function of vaults. The MVP
knockout model and the other vault knockout models discussed above might be used
to directly investigate the physiological significance of the identified interactions.
Identification of VPARP substrates
Finally, more detailed information on the properties of the individual vault
components could give important clues on the physiological function of these
components as well as the whole vault particle. Interesting in this respect is the link
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of vaults with the telomerase complex. Recently, it was reported that besides TEP1
also VPARP and vRNA are found at the telomeres (23). This stresses the need for a
close investigation of the possible cross talk between both ribonucleoprotein
complexes. VPARP is the only vault component with enzymatic activity and may
have more substrates beside itself and MVP. It is now recognized that poly(ADP-
ribosyl)ation is involved in a variety of physiological and pathophysiological
processes, that in addition to base excision repair, DNA-damage signaling and
regulation of genomic stability, includes the regulation of transcription and
proteasomal function (for a review see Bürkle, Ref. 29). Hence, the identification of
additional VPARP substrates could be an important step in the discovery of the
function of this particular protein and the total vault complex.
Anyhow, the strong evolutionary conservation and the abundancy of vaults in many
tissues, argue against a solely ornamental role for vaults, but rather point to a
functional role.
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Summary
The 13 MDa mammalian vault particle consists of multiple copies of a 100 kDa
major vault protein (MVP), the minor vault proteins of 193 kDa (VPARP) and 240
kDa (TEP1) and small untranslated RNA molecules of 88-141 bases. The vault
complex, which is predominantly found in the cytoplasm, has a highly structured
morphology that is conserved between species. Although many reports suggest a
role of vaults in multidrug resistance (MDR), the precise function of this intriguing
particle is yet unknown. In this study we attempted to unravel the physiological
significance of vaults, with particular emphasis on their putative role in MDR.
Chapter 1 gives an overview of the structure, subcellular localization and
characteristics of vaults and vault components and reviews the evidence for a role of
vaults in MDR.
In Chapter 2, the primary sequence of the murine major vault protein is presented
and compared with its orthologues from other species. Over 90% of sequence
identity was found between the human and the murine MVP. Furthermore, the
organization of the murine gene and part of its promoter region is described. The
data are compared with data on the human MVP gene, both genes appear to consist
of 15 exons of which the first is untranslated. Most of the exons of the mouse and
human gene are identical in size. These data once again shows the evolutionary
conservation of MVP and vaults. A region of 421 bp, containing part of the first
exon and 378 bp upstream this exon, contained promoter activity, which could be
enhanced by the presence of the complete first exon. This promoter region shows
58% identity to the homologous human region, suggesting a similar mechanism of
regulation of these two genes.
We generated a MVP knockout mouse model, assuming that disruption of MVP also
leads to disruption of the whole vault particle. The generation and initial
characterization of the MVP knockout mice are presented in Chapter 3. The
knockout mice were born at mendelian ratios and show no clear abnormalities,
indicating that the loss of MVP and vaults does not interfere with the development,
viability and reproduction of mice. If indeed vaults play a role in the protection of
cells to cytotoxic agents, MVP disruption will increase the sensitivity of cells and
animals for these agents. However, disruption of MVP did not affect the sensitivity
of ES cells or bone marrow cells to any cytostatic drug tested. Furthermore, the
activity of the classical MDR proteins P-gp, MRP1 and BCRP was not upregulated
in the MVP-/- cells. Hence, compensation for MVP loss by these proteins seems
unlikely. Finally, the in vivo toxicity of doxorubicin was examined by treating
groups of MVP deficient and wild-type control animals with sublethal doses of
doxorubicin. The MVP knockout mice were found not to be hypersensitive to
doxorubicin. These findings indicate that under our experimental conditions, vaults
do not play a role in the resistance to the examined cytostatic agents.
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The consequences of the disruption of MVP for the integrity of the vault complex
and the stability of the other vault components are investigated in Chapter 4. As
expected, the MVP knockout tissues no longer contain vaults or vault-like particles.
Furthermore, the loss of MVP results in dramatically decreased levels of the minor
vault proteins TEP1 and VPARP, and a 2-fold reduction of the vRNA levels. We
found that the decrease in TEP1 and VPARP protein levels are not caused by
reduced transcription rates, mRNA instability or a translational down regulation.
Most likely, in the absence of the core of the vault, formed by MVP, the minor vault
proteins are unstable. The reduction in vRNA levels is probably a direct result of the
decrease in TEP1 protein. The effects of the loss of MVP are reversible; re-
introduction of full length MVP in knockout cells restored the levels of the VPARP
and vRNA. However, when the coiled-coil domain, the domain responsible for the
interaction between MVP molecules, of the re-introduced MVP is disrupted, the
levels of VPARP and vRNA are not restored. This indicates that VPARP is not
stabilized by binding to MVP, but by interaction with a fully assembled vault
particle.
In Chapter 5 we studied the development and function of dendritic cells derived
from MVP  knockout bone marrow cells. To examine whether these DCs are
impaired in provoking a T cell immune response, MVP deficient mice were
immunized with several allergens. The DCs developed normally, were
phenotypically comparable to wild-type DCs and were not impaired in their T-cell
stimulating capacities. No differences were observed in immune response, induction
of peripheral T cell tolerance and the T cell dependent humoral response.
Macrophages isolated from the mice were able to phagocytose and migrate. In
conclusion, vaults are not required for primary DC functions.
VPARP contains a poly(ADP-ribose)polymerase domain and is a member of the
PARP protein family. Several members of this family are involved in the
maintenance of genomic stability; PARP-1 and PARP-2 are involved in the base
excision repair pathway of DNA damage (BER) and tankyrase-1 and tankyrase-2 are
associated with telomere length regulation. To investigate the possible role of
VPARP and/or vaults in DNA damage repair pathways, MVP-/- MEF cells, with
markedly reduced VPARP levels, were exposed to several DNA damage inducing
conditions (Chapter 6). The cells displayed comparable sensitivity to DNA damage
inducers as the wild-type cells, implying that intact vault particles and most likely
VPARP are not involved in DNA damage repair.
Finally, in Chapter 7, the results of this thesis are summarized and their significance
discussed.
Samenvatting
124
Samenvatting (Summary in Dutch)
Vaults zijn ribonucleoproteïne deeltjes van 13 MDa in grootte en zijn opgebouwd uit
3 eiwitten, het major vault eiwit MVP (100 kDA), TEP1 (240 kDa), VPARP (193
kDa) en meerdere kopieën van kleine, ongetransleerde RNA moleculen (88-140
nucleotiden). Het complex heeft een hoog georganiseerde structuur, die bij
verschillende organismen, van zoogdieren tot de slijmschimmel Dictyostelium
discoideum, vrijwel identiek is. Dit laatste gegeven maar ook het grote aantal vaults
per cel, vastgesteld op 10,000 tot 100,000, suggereren dat het complex een essentiële
functie in de cel verricht. Er zijn verscheidene aanwijzingen dat vaults een rol spelen
in de bescherming tegen toxische stoffen en multidrug resistentie (MDR). MDR is
een vaak voorkomend probleem, waarbij kanker cellen resistent zijn of worden tegen
bestanddelen uit de chemokuur, waardoor de chemotherapie zijn werkzaamheid
verliest. Of vaults daadwerkelijk een rol spelen bij deze resistentie en hoe dit
intrigerende complex werkt is nog niet bekend. Hoofdstuk 1 geeft een overzicht van
de structuur van vaults, de lokalisatie in de cel en de samenstellende componenten,
en bediscussieert de aanwijzingen voor een rol van vaults in multidrug resistentie.
Meer dan 70% van het vault complex bestaat uit het major vault protein MVP. In
Hoofdstuk 2 wordt de opbouw van het muizen MVP gen onderzocht. De resultaten
worden vergeleken met de gegevens die bekend zijn over het MVP gen bij de mens.
De aminozuur volgorde van het muizen en mensen MVP eiwit komen voor meer dan
90% overeen. De gen structuur van het muizen en mensen MVP komt ook overeen.
Beide genen bestaan uit 15 exonen, waarvan het eerste een ongetransleerd exon is.
Ook de grootte van de meeste exonen in het muizen gen is identiek aan de grootte
van de mens-exonen. Deze resultaten benadrukken hoe goed het MVP eiwit en het
vault complex geconserveerd zijn tijdens de evolutie. In het humane MVP gen is een
regio geïdentificeerd die promoter activiteit vertoont, dwz een belangrijke
regulerende functie heeft bij de vertaling van het gen in het MVP eiwit. De
overeenkomstige regio uit het muizengen bevat ook promoter activiteit en is nog
voor ca 60% identiek aan de humane regio. Hieruit kunnen we opmaken dat niet
alleen de opbouw van het muizen en mensen MVP gen sterke overeenkomsten
vertoont, maar ook dat de activatie van de MVP eiwit productie vergelijkbaar
geregeld is bij muis en mens.
Om de mogelijke rol van vaults in multidrug resistentie nader te onderzoeken en om
eventuele andere functies van het complex te achterhalen hebben we een “MVP
knockout” muis model gemaakt. Deze muizen zijn genetisch zo gemanipuleerd dat
ze een gedeelte van het MVP gen missen, en daardoor geen MVP eiwit meer kunnen
produceren. Daarbij hebben we aangenomen dat zonder het belangrijkste
bestandsdeel MVP, geen vault partikels kunnen worden gevormd. Inderdaad blijkt
uit Hoofdstuk 4 dat er geen vaults meer aangetroffen worden wanneer MVP
afwezig is. De MVP knockout muizen bleken levensvatbaar, gezond en fertiel. Dit
duidt erop dat het verlies van MVP (en vaults) geen grote nadelige invloed heeft op
de embryonale ontwikkeling en de normale functie van cellen en organen in de muis.
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Als vaults werkelijk een rol spelen in de bescherming van cellen tegen schadelijke
stoffen, dan zal het verlies van MVP/vaults de cellen (en muizen) gevoeliger maken
voor deze stoffen. We voerden verschillende experimenten uit waarbij de MVP
knockout cellen werden blootgesteld aan verschillende chemokuur bestanddelen
(Hoofdstuk 3). Uit geen enkel experiment bleek dat deze cellen inderdaad
gevoeliger zijn voor een van de onderzochte stoffen. Omdat verscheidene andere
eiwitten die een rol spelen bij MDR mogelijk de functie van vaults overnemen,
hebben we de activiteit van enkele van deze eiwitten getest. De aanwezigheid en
activiteit van P-gp, MRP1 en BCRP bleek onveranderd in de MVP knockout cellen.
Tenslotte werden knockout muizen behandeld met het antikanker medicijn
doxorubicine, maar deze muizen bleken niet gevoeliger te zijn voor de behandeling
dan normale muizen. Deze resultaten suggereren dat onder de geteste condities,
vaults geen rol spelen in de bescherming tegen de onderzochte medicijnen.
De biologische effecten van het verlies van MVP op het vault deeltje werden
onderzocht in Hoofdstuk 4. Zoals we hadden verondersteld bevatten de organen van
de MVP knockout muizen geen vaults meer. Behalve dat blijkt het verlies van MVP
ook een grote invloed te hebben op de hoeveelheid van de andere vaultbestanddelen;
TEP1, VPARP en vRNA. Uit verdere experimenten bleek dat de vermindering van
de TEP1 en VPARP eiwitten niet veroorzaakt werd door een verminderde productie,
maar door een verminderde stabiliteit en verkorte levensduur van deze eiwitten. Als
de knockout cellen weer voorzien werden van MVP, stegen de hoeveelheden van
TEP1, VPARP en vRNA ook weer. Tevens bleek dat de overige vault bestanddelen
alleen gestabiliseerd kunnen worden door uit MVP opgebouwde vault deeltjes, en
niet door losse MVP moleculen.
In Hoofdstuk 5 hebben we onderzocht of het uitschakelen van MVP in de muis
gevolgen heeft voor de ontwikkeling en het functioneren van dendritische cellen, een
cel type dat een belangrijke rol speelt tijdens de activatie van het immuunsysteem.
Om te testen of de dendritische cellen van de MVP knockout muizen een
verminderde capaciteit hebben om de immuunreactie op gang te brengen, werden
MVP knockout muizen geïmmuniseerd met verschillende allergene stoffen. Uit
celkweek experimenten bleek dat de dendritische cellen van de MVP knockout
muizen zich normaal ontwikkelden en (in celkweek systemen) in staat waren om
andere cellen uit het immuunsysteem, de T-cellen, te activeren. De immuunreactie
van de muizen op de verschillende allergenen was identiek aan de reactie van
normale controle muizen. Dit wijst erop dat ook in de muis, de MVP knockout
dendritische cellen zich normaal gedragen.
VPARP, een van de vault eiwitten, heeft een zogenaamd poly(ADP-
ribose)polymerase domein en behoort tot de PARP-eiwit familie. Van enkele
eiwitten van deze familie (PARP-1 en PARP-2) is aangetoond dat ze een rol spelen
bij het herstel van DNA schade. Wellicht is ook VPARP belangrijk in DNA-schade
herstel. Om deze hypothese te toetsen hebben we MVP knockout cellen, waarin de
niveaus van VPARP sterk verlaagd zijn, behandeld met stoffen en condities die
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schade aan het DNA veroorzaken (Hoofdstuk 6). Deze cellen bleken echter even
gevoelig voor de geïnduceerde DNA schade als de normale cellen, waaruit we
kunnen concluderen dat het verlies van MVP en vaults en het verminderde niveau
van VPARP geen effect hebben op DNA reparatie mechanismen.
Tenslotte worden de resultaten samengevat en bediscussieerd in Hoofdstuk 7.
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List of Abbreviations
7-AAD 7 amino actinomycin D
ALL acute lymphoblastic leukemia
AML acute myeloid leukemia
BCRP breast cancer resistance protein
BER base excision repair
bp base pair
CD cluster of differentiation
cDNA complementary DNA
DC dendritic cell
ES cells embryonic stem cells
FCS fetal calf serum
FIGO federation of gynaecology and obstetrics
FLT-3 fetal-liver tyrosine kinase-3
GFP green fluorescent protein
GM-CSF granulocyt-macrophage colony-simulating factor
IL interleukin
ko knockout
LIF leukemia inhibitor factor
LRP lung resistance-related protein
mAb monoclonal antibody
MDR multidrug resistance
MEF mouse embryonic fibroblast
MiVP minor vault protein
MLR mixed lymphocyte reaction
MM multiple myeloma
MRP multidrug resistance protein
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
MVP major vault protein
NER nucleotide excision repair
OS overall survival
PARP poly(ADP-ribose) polymerase
PBS phosphate-buffered saline
PCR polymerase chain reaction
P-gp P-glycoprotein
RT-PCR reverse transcriptase polymerase chain reaction
SCF stem cell factor
TEP1 telomerase-associated protein 1
TPO trombopoietin
VPARP vault PARP
vRNA vault RNA
wt wild-type
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